BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the Accusation Against:

SANTA CLARA DRUG “THE COMPOUNDING SHOP”

Retail Pharmacy License No. PHY 51229

VISHAL B. PUROHIT

Registered Pharmacist License No. RPH 62617

Respondents.

Case No. 5380
OAH No. 2015110018

ORDER DENYING RECONSIDERATION

On July 19, 2016, respondent timely filed a petition for reconsideration of the California State Board of Pharmacy’s (Board’s) Decision and Order dated June 29, 2016. The Board, having read and considered the petition, as well as the opposition to the petition filed by the complainant, hereby denies the petition.

The June 29, 2016, Decision and Order is the Board’s final decision in this matter. That decision will become effective at 5:00 p.m. on July 29, 2016, as originally ordered.

IT IS SO ORDERED this 29th day of July, 2016.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

Amy Gutierrez, Pharm.D.
Board President
BEFORE THE 
BOARD OF PHARMACY 
DEPARTMENT OF CONSUMER AFFAIRS 
STATE OF CALIFORNIA 

In the Matter of the Accusation and Petition to 
Revoke Probation Against: 

SANTA CLARA DRUG “THE 
COMPOUNDING SHOP” 

Retail Pharmacy License No. PHY 51229 

VISHAL B. PUROHIT 

Registered Pharmacist License No. RPH 62617 

Respondents. 

Case No. 5380 

OAH No. 2015110018 

DECISION AND ORDER 

The attached Proposed Decision of the Administrative Law Judge is hereby adopted 
by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter. 

This Decision shall become effective at 5:00 p.m. on July 29, 2016. 

It is so ORDERED on June 29, 2016. 

BOARD OF PHARMACY 
DEPARTMENT OF CONSUMER AFFAIRS 
STATE OF CALIFORNIA 

By 

Amy Gutierrez, Pharm.D. 
Board President
PROPOSED DECISION

Administrative Law Judge David L. Benjamin, State of California, Office of Administrative Hearings, heard this matter on April 4, 5 and 13, 2016, in Oakland, California.

Deputy Attorney General Rosailda Perez represented complainant Virginia Herold, Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

Herb L. Weinberg, Attorney at Law, Fenton Law Group LLP, represented respondent Santa Clara Drug "The Compounding Shop," and respondent Vishal B. Purohit, who was present.

The record closed and the matter was submitted on April 13, 2016.
FACTUAL FINDINGS

Respondents

1. On July 28, 2009, the Board of Pharmacy (Board) issued Registered Pharmacist License Number RPH 62617 to respondent Vishal B. Purohit (respondent). The Registered Pharmacist License was in full force and effect at all times relevant to this proceeding and will expire on November 30, 2016, unless renewed.

2. On March 8, 2013, the Board issued Retail Pharmacy License Number PHY 51229 to ERA Pharmacy Inc., dba Santa Clara Drug “The Compounding Shop” (respondent Pharmacy). The Retail Pharmacy License was in full force and effect at all times relevant to this proceeding and will expire on March 1, 2017, unless renewed.

3. Respondent is a highly-educated pharmacist. He has pharmacy degrees from institutions in India and the United States, a master’s degree in pharmacology from St. John’s University in New York, a doctorate in pharmacology from the University of Arizona, and a doctor of pharmacy degree from the University of Colorado in Denver. Respondent used his life savings to purchase Santa Clara Drug in March 2013; he is the sole owner and the pharmacist-in-charge of respondent Pharmacy. Respondent Pharmacy is the sole source of income for respondent, his wife and their three children; respondent’s wife also works at the pharmacy. Several persons familiar with respondent Pharmacy wrote letters stating that the pharmacy does a good job and performs an important community service.

4. Unlike a regular pharmacy, which dispenses pharmaceuticals approved by the Food and Drug Administration (FDA), a compounding pharmacy makes pharmaceuticals in various forms pursuant to a physician’s order for a particular patient. These prescriptions may call for the use of controlled substances. The pharmaceuticals dispensed by a compounding pharmacy can directly affect public health. The pharmacist-in-charge of a compounding pharmacy is responsible for insuring that the pharmacy complies with federal and state laws and regulations. While compounding pharmacies are closely regulated, public safety still relies heavily on the knowledge and good judgment of the pharmacist-in-charge.

Respondents’ disciplinary history

5. On July 26, 2013, in Case No. 4842, complainant issued an accusation against respondent Pharmacy and against respondent in Case No. 4842. The accusation alleged that respondents violated the laws and regulations that govern pharmacy practice in several respects, summarized as follows:

   a. From March 2013 to June 2013, respondents compounded sterile injectable drug products without a license to do so.

   b. Respondents compounded multiple batch-produced sterile injectable drug products from one or more non-sterile ingredients, and released those products for sale
and/or patient administration, without first quarantining the sterile injectable drugs for appropriate testing.

c. Respondents failed to make and retain records for the multiple batch-produced sterile injectable drug products they compounded between April 2013 and June 2013.

d. Respondent did not timely complete a self-assessment, or a compounding pharmacy self-assessment, as required by regulation.

e. Respondents kept multiple expired drugs throughout the pharmacy, including in the extemporaneous compounding area, the sterile injectable product compounding area, the main pharmacy dispensing area, and in an unclean refrigerator.

6. Respondents entered into a Stipulated Settlement and Disciplinary Order with the Board, which took effect on August 30, 2013. In that Stipulated Settlement, respondents admitted the truth of the allegations in the accusation. Under the terms of the Disciplinary Order, the licenses of respondent Pharmacy and respondent were revoked, but the revocations were stayed and the licenses were placed on probation for five years, subject to terms and conditions.

7. Condition 9 of respondent Pharmacy’s probation states:

Respondent Pharmacy shall, upon or before the effective date of this decision, ensure that all employees involved in permit operations are made aware of all the terms and conditions of probation, either by posting a notice of the terms and conditions, circulating such notice, or both. If the notice required by this provision is posted, it shall be posted in a prominent place and shall remain posted throughout the probation period.

Respondent Pharmacy shall ensure that any employees hired or used after the effective date of this decision are made aware of the terms and conditions of probation by posting a notice, circulating a notice, or both. Additionally, Respondent Pharmacy shall submit written notification to the Board, within fifteen (15) days of the effective date of this decision, that this term has been satisfied. Failure to submit such notification to the Board shall be considered a violation of probation.

8. Condition of 11 of respondent Pharmacy’s probation states, in relevant part, as follows:

Respondent Pharmacy shall prominently post a probation notice provided by the Board in a place conspicuous and readable to
the public. The probation notice shall remain posted during the entire period of probation.

Failure to post such notice shall be considered a violation of probation.

9. Condition 21 of respondent’s probation states, in relevant part, as follows:

During the period of probation, Respondent Pharmacist shall not supervise any intern pharmacist, be the pharmacist-in-charge or designated representative-in-charge of any entity licensed by the Board nor serve as a consultant unless otherwise specified in this order.

Condition 32 permits respondent to be a pharmacist-in-charge, notwithstanding Condition 21, but reiterates the prohibition against supervising any intern pharmacist.

Pharmacy inspections; first amended accusation and petition to revoke probation

10. Board Inspector Hilda Nip, Pharm.D., conducted a quarterly inspection of respondent Pharmacy on March 14, 2014. Nip, accompanied by Board Supervising Inspector Michael Ignacio, Pharm. D., also inspected respondent Pharmacy on June 3, 2014, March 19, 2015, and July 22, 2015. Nip and Ignacio are licensed California pharmacists. Nip has been licensed since 1993. Before she became a Board inspector in 2008, Nip worked as a retail pharmacist and as the pharmacist-in-charge at a Kaiser facility from 2001 to 2008. In her work with the Board, she has inspected over 300 pharmacies. Ignacio became a licensed pharmacist in 2009. He worked in retail pharmacies and in compounding pharmacies until he became a Board inspector in March 2014. Ignacio has done over 100 inspections. By Board policy, all of Nip’s and Ignacio’s inspections of respondent Pharmacy were unannounced. At each inspection, respondent was present. He greeted the inspectors, provided access to the pharmacy, discussed the inspectors’ findings with them, and was asked, or was given the opportunity, to submit post-inspection statements.

11. After these inspections, on January 14, 2016, Virginia Herold, acting in her official capacity as the Executive Director of the Board, issued a first amended accusation and petition to revoke probation against respondents. In that document, complainant alleges that respondents violated various federal and state laws and regulations governing pharmacy practice. Respondents filed a notice of defense and this hearing followed.

PHARMACIST/TECHNICIAN RATIO (FIRST ALLEGED CAUSE FOR DISCIPLINE)

12. Business and Professions Code section 4115, subdivision (f)(1), states that “[a] pharmacy with only one pharmacist shall have no more than one pharmacy technician.”
performs the duties a technician is licensed to perform. Subdivision (a) of section 4115 provides that a pharmacy technician “may perform packaging, manipulative, repetitive, or other nondiscretionary tasks, only while assisting, and while under the direct supervision and control of a pharmacist.” “Nondiscretionary tasks” include removing drugs from stock. (Cal. Code Regs., tit. 16, § 1793.2, subd. (a).)

13. At their June 3, 2014 quarterly inspection, Inspectors Nip and Ignacio observed three pharmacy technicians, Digita Patel, Sejal Mehta and Andrea Salazar, performing technician duties while only one pharmacist — respondent — was on duty. Nip observed Salazar unpacking and stocking drugs, and counting tablets with a counting tray and a spatula in the dispensing area. Nip and Ignacio saw Patel and Mehta begin the preparation of two prescriptions by removing ingredients from stock, and pouring, weighing and mixing the ingredients to compound the prescriptions.

14. Technicians Patel and Mehta informed the inspectors that there were usually two pharmacists on duty, respondent and George Martin, but that Martin had been on vacation since May 29 and respondent was the only pharmacist on duty. Respondent also told the inspectors that Martin was on a one-week vacation that began on May 29, and that he was due back to work on June 5. Respondent repeatedly asked the inspectors to give him advance notice of future inspections.

15. Later during the same inspection, respondent gave a different explanation for Martin’s absence. He told the inspectors that Martin was not at work on June 3 because he was on emergency leave due to his wife’s medical condition; he asked the inspectors to change their report to so state. In a declaration he wrote on June 27, 2014, Martin wrote that he and his wife, who has serious medical conditions, had driven to Oregon on May 29; he was scheduled to work on June 3, Martin writes, but took an “unplanned and unscheduled day off” because of his wife’s condition. At hearing, Martin and respondent testified to the same effect.

16. In declarations they wrote later, the technicians denied that more than one of them performed licensed activities on June 3. None of the technicians testified at hearing and their declarations were admitted as hearsay.

17. In a written statement he prepared later, respondent writes that on June 3 he was taken by surprise when he learned at the last minute that Martin would not be reporting to work. It was too late, respondent writes, to send the technicians home so he called “a quick meeting” with his staff and informed them that only Mehta was to perform technician duties that day. In his statement, respondent denies that any of the other technicians performed licensed activities on June 3.

18. At hearing, however, respondent testified that on June 3 he left it to his staff members to decide who would perform technician duties that day. He acknowledged that more than one technician may have done so.
19. The testimony of Nip and Ignacio is credible and persuasive. They have a clear understanding of what constitutes licensed activity for a pharmacy technician, and they have no reason to misstate what they observed on June 3. Little weight is given to respondent's testimony on this issue. Respondent's claim that he did not expect to be the only pharmacist on duty on June 3 is not credible; it is inconsistent with his first statement to the inspectors, and the first statements of his staff, that Martin was scheduled to be on vacation until June 5. Respondent's claim that only one technician performed technician duties is belied by his later admission that more than one technician may have done so.


21. Respondents were not found to be in violation of the pharmacist/technician ratio at any of the other inspections performed by Nip and Ignacio.

LABELING OF PRESCRIPTION DRUG CONTAINERS (SECOND AND THIRD ALLEGED CAUSES FOR DISCIPLINE)

22. Business and Professions Code section 4076, subdivision (a)(11)(A), provides (in relevant part) that a pharmacist shall not dispense any prescription "except in a container that . . . is correctly labeled with . . . the physical description of the dispensed medication, including its color, shape and any identification code . . . ." In addition, labels on drug containers must list "either the manufacturer's trade name of the drug, or the generic name and the name of the manufacturer." (Cal. Code Regs., tit. 16, § 1707.5, subd. (a)(1)(B).)

23. At the June 3, 2014 inspection, Nip examined the will call area of the pharmacy that contains drugs ready to be picked up. She found a container of medication for patient DP with tablets from two different manufacturers, separated by a piece of cotton. The tablets were the same medication. The label on the container did not state the names of the manufacturers, a physical description of the medication, or their identification codes.

24. Respondent told the inspectors he had always inserted a piece of cotton to separate medications from different manufacturers, and then placed an auxiliary label on the container to alert the consumer that the medications were the same but from different manufacturers. Informed by the inspectors that the practice he described was not permitted, respondent stated that it was not his usual practice.

25. At hearing, respondent produced a letter from RP dated September 24, 2015. (RP did not testify and the letter was admitted as hearsay.) RP writes that he is the son of DP, who is 90 years old. RP states that respondent Pharmacy told him it could not fill his mother's prescription with medications from one manufacturer, and offered to separate the medications into two different containers. RP states that he asked for one container because two containers would confuse his mother. He goes on to write that the container had a sticker on it that said, "This is the same medication you have been getting. Color size or shape may appear different."

QUALITY ASSURANCE FOR COMPOUNDED DRUG PRODUCTS (FOURTH ALLEGED CAUSE FOR DISCIPLINE)

27. California Code of Regulations, title 16, section 1735.8, subdivisions (a) and (c), provide in relevant part as follows:

(a) Any pharmacy engaged in compounding shall maintain, as part of its written policies and procedures, a written quality assurance plan designed to monitor and ensure the integrity, potency, quality, and labeled strength of compounded drug products.

28. On March 14, 2014, Nip examined respondents' records to assess his compliance with this regulation. She told respondent she thought the pharmacy was not in compliance.

29. Inspectors Nip and Ignacio examined respondents' records for compliance again when they inspected the facility on June 3, 2014. Respondents maintain written "standard operating procedures" (SOP's). SOP 9.140 addresses "Non-sterile compounding process validation," and SOP 9.150 concerns "Non-sterile compounding finished preparation testing." These provisions identify certain steps pharmacy personnel must follow regarding physical and particulate testing of the finished product, verifying the accuracy of the product, and verifying the compounding record, the fill volumes and the quantities of the units prepared. The SOP's do not require that every compounded product be sent to an independent laboratory to be tested for potency. Section 9.3.4 of SOP 9.150 provides that "At the discretion of the Pharmacist-in-charge, samples shall be tested for potency using the appropriate method or samples shall be sent to a contract lab for testing."

Nip concluded that respondents were not following "the law or their own policies" for qualitative and quantitative analysis. In particular, Nip testified, she was looking to see whether respondents had conducted some studies or analyses of potency, and she did not see
any evidence that such studies were done. Such studies, Nip stated, are usually done by an outside laboratory. In this case, respondents never claimed the ability to perform potency testing in-house, and she saw no evidence that respondents had sent their products to an outside laboratory for testing.

In his declaration dated June 9, 2014, Ignacio writes,

PIC Purohit provided the policies and procedures of Santa Clara Drug Pharmacy for Inspector Nip and me to review. The policies and procedures for quality assurance stated a qualitative and quantitative analysis would be done for all compounded medications done by Santa Clara Drug Pharmacy. Inspector Nip and I asked if PIC Purohit did an analysis of the prescriptions compounded by the pharmacy. PIC Purohit said he has not done any analysis of any prescriptions compounded by the pharmacy.

30. Inspector Nip acknowledged at hearing that the regulation at issue, section 1735.8, does not require qualitative and quantitative testing of every product compounded by respondents. The regulation does not require it, and it would not be practical to impose such a requirement on every patient-specific prescription: it takes a laboratory several days to perform potency testing, during which time the patient would have to wait for his or her medication, and the potency testing alone costs several hundred dollars. Similarly, and contrary to Ignacio’s declaration, respondents’ SOP’s do not require potency testing “for all compounded medications done by” respondent Pharmacy. The SOP’s state, in essence, that potency testing will be performed at the discretion of the pharmacist-in-charge.

31. The accusation alleges that respondents “failed to demonstrate quality assurance in the form of qualitative and quantitative analysis of compounded drug preparations.” This allegation appears to be based on the premise that respondents were obligated by section 1735.8 or their own SOP’s to do potency testing of all compounded drug preparations, a premise that is not supported by the evidence.

32. The evidence fails to establish that respondents violated section 1735.8.

BIENNIAL INVENTORY OF SCHEDULE III TO V CONTROLLED SUBSTANCES (FIFTH ALLEGED CAUSE FOR DISCIPLINE)

33. Pursuant to federal regulation, respondents are required to “take a new inventory of all stocks of controlled substances on hand at least every two years.” (21 C.F.R. § 1304.11(c).)

34. When she inspected respondent Pharmacy on March 14, 2014, Nip asked to examine respondents’ biennial inventory. Respondent produced it. The inventory respondent gave Nip was a handwritten document with a cover page that stated the date of
each inventory, in a column, in chronological order from the oldest to the most recent, as follows:

1990
4/24/92
9-6-93
12/30/95
08/03/09
5/5/10
4/25/12

Nip noticed that the last inventory was done on April 25, 2012. She told respondent that, by federal regulation, his next inventory had to be completed in a little more than a month, by April 25, 2014.

35. When she returned to respondent Pharmacy on June 3, 2014, Nip asked to see respondents’ biennial inventory. Respondent gave her the same document he had produced on March 14. The cover page of the inventory still reflected that the last inventory had been done on April 25, 2012. Respondent apologized to Nip for missing the deadline. He told her he would perform the inventory that day and fax it to her. Respondent performed the inventory on June 3, and faxed it to Nip on June 4. The cover page of the inventory respondent faxed to Nip was exactly the same as the cover page he had shown her on March 14 and on June 3, except that under the date “4/25/12,” respondent had written “6/3/14” and initialed it.

36. Approximately a week before this hearing in April 2016, respondent produced to complainant’s counsel a different version of the controlled substances inventory, identified at hearing as Exhibit J. Exhibit J has the same cover page as the June 3, 2014 inventory respondent faxed to Nip except that, in between the inventory dates of “4/25/12” and “6/3/14,” is written “5/14/13” and the initials of pharmacist Gary Martin. Underneath the cover page, the document that follows is completely different from the original inventory. There are still drugs listed in a column along the left, but the drugs are in a different order. There are still columns with dates at the top, but the dates are not consistent with the inventory dates on the cover page, and they are not consistent throughout the document itself. For example, on page J4, the sequence of inventory dates is


On page J25, the sequence of dates is


37. Martin testified that he did a controlled substance inventory on May 14, 2013, “for the new owner.” (Respondent became the owner of respondent Pharmacy in March 2013.) According to Martin, he made a record of that inventory and then, at some time not
stated, he “found it.” He states that he “recreated” the inventory in Exhibit J; according to Martin, most of the handwriting on Exhibit J is not his. Martin did not state exactly when he recreated the inventory, but he did it after the inspectors came to the pharmacy in June 2014, and he did it at respondent’s request. Asked how he “recreated” the May 14, 2013 inventory in Exhibit J when the document has dated columns before and after May 14, 2013, Martin testified

by moving dates into . . . around . . . because we weren’t very careful with how we did these things and there was space to put it in. There were probably blank columns before the other dates. We’re trying to do this while we’re working and so you’ve got telephone calls and you’ve got patients and I’m trying to get this done.

Respondent believes that Martin did an inventory on May 14, 2013; he asserts it was not noted on the cover page of the inventories he produced to Inspector Nip because of a “technical error.” He did not explain what that technical error was.

38. The accusation alleges that respondent “failed to conduct a biennial inventory within the required time frame.” The evidence is clear that he failed to do so. Inspector Nip asked to see respondent’s biennial inventory on March 14, 2014. The document revealed that the last inventory was done on April 25, 2012, and therefore that the next inventory was due on or before April 25, 2014. Nip reminded respondent that he needed to complete the inventory shortly. When Nip returned in June 2014 and asked to look at his controlled substance inventory, respondent gave her the same document. When Nip informed him that he had not completed the inventory by April 25, 2014 as required, respondent apologized and performed an inventory that day. At no time during any of the inspections did respondent tell Nip that the pharmacy had done an inventory in 2013, or that the next inventory was not due until 2015, or that he maintained his controlled substance inventory in another document.

Exhibit J is not trustworthy or persuasive evidence that an inventory was done on May 14, 2013. To begin with, even Martin does not assert that Exhibit J is the inventory he claims he took on May 14, 2013. By his own admission, it is a “recreation” of the inventory Martin claims he found. The inventory Martin claims he found was not offered into evidence. Respondent’s failure to assert the existence of a May 2013 inventory until the eve of hearing, and Martin’s vague description of the “recreation” of such an inventory, makes it impossible to have any confidence in the authenticity or reliability of Exhibit J.

39. Respondents failed to conduct a biennial inventory within the time required by federal regulation.
DISCLOSURE OF RESPONDENT PHARMACY’S PROBATIONARY STATUS TO PHARMACY EMPLOYEES (SIXTH ALLEGED CAUSE FOR DISCIPLINE)

40. When a pharmacy permit is on probation, the pharmacy must “[p]ost or circulate notice of conditions of probation so that they are available to all employees involved in pharmacy operations.” (Cal. Code Regs., tit. 16, §1774, subd. (a)(4).)

41. After the June 3, 2014 inspection, Inspector Nip contacted Stephanie Armstrong, a pharmacist intern at respondent Pharmacy. Armstrong sent Nip an email in which she stated she was unaware that respondent or respondent Pharmacy was on probation. Nip testified that, in a telephone conversation with technician Salazar, Salazar told her she did not know respondent or respondent Pharmacy was on probation. (Armstrong and Salazar later recanted their statements.)

42. Respondent testified, without contradiction, that notice of respondent Pharmacy’s probationary status was posted in the employee break room. Although Armstrong and Salazar may have been unaware of respondents’ probationary status, section 1774 permits a pharmacy to give notice to its employees by posting.

43. The evidence does not establish that respondent violated section 1774, subdivision (a)(4).

SUPERVISION OF INTERN PHARMACISTS (SEVENTH ALLEGED CAUSE FOR DISCIPLINE)

44. A pharmacist on probation to the Board may “[n]ot supervise any registered interns nor perform any of the duties of a preceptor.” (Cal. Code Regs., tit. 16, § 1773, subd. (a)(6).)

45. When she inspected respondent Pharmacy on June 3, 2014, Nip observed prescription verification labels that bore the initials of interns Armstrong and Catherine Selim, with respondent’s initials alongside the initials of the interns. This indicated to Nip that respondent was supervising the work of the interns. Respondent told the inspectors that pharmacist Martin routinely approves the work of the interns, but that sometimes Martin was busy and respondent himself had to verify prescriptions. As noted above, Martin was not at work on June 3.

46. The evidence establishes that, on June 3, 2014, respondent supervised interns in violation of California Code of Regulations, title 16, section 1773, subdivision (a)(6)).

47. Complainant argues that a “Pharmacy Intern Hours Affidavit” respondent signed on March 2, 2014, is further evidence that he supervised intern Armstrong. The affidavit attests that Armstrong worked as an intern pharmacist for 158 hours between February 26 and March 27, 2014. The affidavit, however, does not state that respondent supervised Armstrong, as the form states that it may be completed by “the pharmacist under whose supervision such experience was obtained or by the pharmacist-in-charge.”
Complainant asserts that, by signing the affidavit, respondent falsely stated that his license is not on probation. The first amended accusation, however, does not allege respondent's signature on that document as cause for discipline.

POSTING OF THE NOTICE OF PROBATION (EIGHTH CAUSE FOR DISCIPLINE)

48. California Code of Regulations, title 16, section 1774, subdivision (a)(4), states that any pharmacy on probation shall "[p]ost or circulate notice of conditions of probation so that they are available to all employees involved in pharmacy operations." Subdivision (b) of that section states that the Board may impose conditions of probation in addition to those set forth in subdivision (a). Condition 11 of respondent Pharmacy's probation states that respondent Pharmacy shall "prominently post a probation notice in a place conspicuous and readable to the public." When respondents' probationary period began, the Board provided respondent Pharmacy with a yellow probation notice to post.

49. At the June 3 inspection, Nip saw that the yellow Notice of Probation was taped to a sliding pocket door between the waiting room and another office; the sliding door was open, and therefore the Notice was not visible. There was another sign on the same door, stating that the door must be kept closed during business hours. Respondent told Nip that the door was always closed, but was open at that time only because a supplier was transferring stock from one room to another. Nip instructed respondent to place the notice in a stationary place, such as a wall, so that it would be conspicuous and readable to the public at all times.

50. On August 29, 2014, in the evening, Inspector Nip drove by respondent Pharmacy and saw that the Notice of Probation was posted on a window on the side of the pharmacy, so that the printed matter on the Notice was facing outward toward the alley. The Notice was half-covered by a neon sign in the window.

51. Nip and Ignacio returned to respondent Pharmacy for an inspection on January 28, 2015, and found the Notice in the same place, in the window facing the alley. They instructed respondent to place the sign on a wall inside the pharmacy where it would be readable by consumers. Respondent asked if he could post it on the side of a counter, below waist level. Nip told him that, in that location, it would not be conspicuous to customers.

52. When Nip and Ignacio returned to respondent Pharmacy on March 19, 2015, the yellow Notice was posted on the side of a counter, where Nip had told respondent not to put it. The Notice was folded in half so that it was not readable; all that was visible was a blank yellow sheet.

53. Respondent told Nip that the Notice was folded because the tape holding it on had become loose. His explanation is not consistent with the fold in the Notice, or with his prior efforts to post the Notice in a place where it would not be conspicuous to the public.
54. Respondents repeatedly violated their obligation to post the Notice of Probation in a place where it would be conspicuous and readable to the public.

COMPOUNDING AND DISPENSING PRESCRIPTIONS CONTAINING DOMPERIDONE (NINTH AND TENTH ALLEGED CAUSES FOR DISCIPLINE)

55. Under Health and Safety Code section 111400, a drug is “misbranded” if is “dangerous to health when used in the dosage, or with the frequency or duration prescribed, recommended or suggested in its labeling.” It is unlawful for any person to sell any drug that is misbranded. (Health & Saf. Code, § 111440.) It is also unlawful for any person to sell a “dangerous drug” that is misbranded. (Bus. & Prof. Code, § 4169, subd. (a)(3).) The term “dangerous drug” is defined by Business and Professions Code section 4022. Under federal law, a drug is misbranded unless its labeling bears adequate warnings against use “in those pathological conditions . . . where its use may be dangerous to health . . . .” (21 U.S.C. §352(f).)

56. Domperidone is a dangerous drug within the meaning of Business and Professions Code section 4022 that is associated with two general purposes: to stimulate the production of breast milk in lactating women, and for certain gastrointestinal disorders. Domperidone presents serious health risks to lactating women, including cardiac arrhythmias, cardiac arrest and sudden death. For many years, the FDA has banned the use of domperidone in the United States unless there has been an approved “Investigational New Drug” filing (IDA).

57. On March 18, 2015, respondent left a voicemail message for Inspector Nip, and sent her an email, asking whether he could compound with domperidone. In his voicemail message, respondent told Nip that domperidone “is a drug mainly used in GI issue [sic] for GI motility.” Because she knew that the FDA had banned the use of domperidone, Nip was concerned about respondent’s message and she responded to the pharmacy the next day, with Inspector Ignacio.

58. On March 19, Nip found domperidone among the active inventory at respondent Pharmacy. One of respondent’s technicians acknowledged that the pharmacy had compounded with domperidone within the past six months. A review of respondent’s compounding records showed that 10mg, 20mg and 30mg domperidone capsules had been compounded multiple times during the past year. When the inspectors later reviewed respondents’ compounding records from January 1, 2014 to February 28, 2015, they found respondents had compounded 52 prescriptions for domperidone capsules, and dispensed 48 of those prescriptions. Almost all of the prescriptions were written by obstetrics/gynecology

1 Under Health and Safety Code section 111355, a drug “is misbranded if its labeling or packaging does not conform to the requirements of Chapter 4 (commencing with Section 110290).” Although the accusation alleges that respondents violated section 111355, it does not state what provisions of Chapter 4 respondents failed to conform to.
physicians or family practitioners, for female patients. Respondents did not have an IDA that allowed the dispensing of domperidone.

59. When she met with respondent on March 19, Nip informed him that he should not be compounding with domperidone, and asked him if he had visited the FDA’s website, and the Board’s website, for information about domperidone. Respondent stated that he had but that he found the information “very confusing.” He stated that the FDA’s website suggested he could compound with domperidone if he had an “exemption”; he could not explain what type of exemption would allow him to compound with domperidone and acknowledged that, in any event, he did not have an exemption. Respondent asserted that he dispensed domperidone to patients with gastrointestinal conditions, but his records revealed that only a handful of prescriptions were dispensed for that purpose. Respondent insisted that the information about domperidone was unclear, and that he was justified in filling the prescriptions based upon the physician’s order. He contested the FDA’s “jurisdiction” over pharmacies and argued that the risks of domperidone were based on its intravenous use, not its oral use. Nip and Ignacio confiscated respondent’s inventory of domperidone.

60. In an email to Nip on March 19, respondent stated that he had done additional research which “clears up to some extent which primary literature was used by FDA to come up with [the] conclusion about . . . [cardiac] arrhythmias, breast milk excretion, etc. . . . Please note there is no debate. We have [s]topped compounding domperidone as of today. There are a lot more compounding pharmacies in CA who are still doing it please make sure that they all stop compounding it.”

61. The week before this hearing in April 2016, respondent submitted a written statement to complainant in which he asserted that he emailed Nip on February 16, 2015, and asked her whether he could compound with domperidone. Respondent writes that he did not receive an answer, which “led [him] to believe it is OK to compound.” As proof of the email he sent to Nip, respondent produced not a copy of the actual email itself, but a “forwarded message” purporting to be an email from respondent to Nip. Nip has searched her inbox and her deleted messages, which she has retained dating back to 2012, and has found no email from respondent to her on February 16, 2015. The evidence fails to support respondent’s assertion that he emailed Nip about compounding domperidone on February 16, 2015.

62. Respondent states that he believed it was permissible to compound with domperidone because he bought the drug from a licensed wholesaler, and because he was advised by a consultant for the Professional Compounding Centers of America that it was “OK to compound Domperidone.”

MARKING OF COMPOUNDED CAPSULES (ELEVENTH ALLEGED CAUSE FOR DISCIPLINE)

64. A person may not sell or transfer any dangerous drugs that the person “knew or reasonably should have known were adulterated, as set forth in Article 2 (commencing with Section 111250) . . . of the Health and Safety Code.” A drug is “adulterated if it consists, in whole or in part, of any filthy, putrid, or decomposed substance.” (Health & Saf. Code, § 111250.)

65. On July 22, 2015, Inspectors Nip and Ignacio inspected respondent Pharmacy. In the will call area, Ignacio found several prescription containers of compounded white capsules. The white capsules were all marked with a small color streak. Respondent told Ignacio that the streaks represented color-coding used to identify the capsules. He stated that the pharmacy used diluted food coloring paste to make the streaks. Respondent’s explanation seemed improbable to Ignacio, who thought that water-based food coloring would dissolve the capsules.

66. Ignacio asked one of the pharmacy technicians in the compounding area how they marked the capsules. The technician showed Ignacio a container of colored markers and told him that they used the markers to put the color streaks on the capsules. In the container were 17 markers of various colors. Four of the markers bore the tradename Wilton Food Writer, and the notation “edible.” The other 13 markers were “RoseArt” and “Crayola” markers which bore the statement “non-toxic,” but did state “edible.” Respondent told Ignacio and Nip that he would no longer use those markers.

67. Complainant asserts that capsules marked with the RoseArt and Crayola markers were adulterated. Complainant’s assertion appears to be based on the proposition that if a marker states it is “non-toxic,” but does not state that it is “edible,” then it must consist of “filthy, putrid or decomposed substance.” The evidence fails to support this premise. The evidence does not establish that the capsules were adulterated within the meaning of Health and Safety Code section 111250.

PRESCRIPTION FOR COMPOUNDED CREAM CONTAINING A CONTROLLED SUBSTANCE
(TWELFTH, THIRTEENTH AND FOURTEENTH ALLEGED CAUSES FOR DISCIPLINE)

68. Every prescription for a Schedule II through V controlled substance must be made on a California Security Prescription form that meets the requirements of Health and Safety Code section 11162.1. (Health & Saf. Code, § 11164, subd. (a).) A controlled substance may be dispensed on an oral prescription under certain circumstances. (Health & Saf. Code, § 11164, subd. (b).)

69. With exceptions not pertinent here, a pharmacy shall maintain a medication profile of all patients who have prescriptions filled at the pharmacy. (Cal. Code Regs., tit. 16, § 1707.1, subd. (a).) For each prescription, the patient medication record shall include the “name, strength, dosage form, route of administration . . . quantity and directions for use” (subd. (a)(1)(B)1); the date on which a drug was dispensed (subd. (a)(1)(B)3); and, if a
prescription is refilled, a record of each refill, the quantity dispensed, and the initials of the dispensing pharmacist (subd. (a)(1)(B)5); Cal. Code Regs., tit. 16, § 1717, subd. (b)(3).)

70. The Department of Justice maintains the Controlled Substance Utilization Review and Evaluation System (CURES) for electronic monitoring of the prescribing and dispensing of controlled substances. (Health & Saf. Code, § 11165.) For each prescription of a Schedule II through IV controlled substance, the dispensing pharmacy must report to the Department of Justice the pharmacy prescription number (subd. (d)(3)), the quantity of the controlled substance dispensed (subd. (d)(5)), and the date of dispensing of the prescription (subd. (d)(10)).

71. On June 18, 2015, the Board received a complaint from Harpreet Singh, M.D., concerning a prescription he had written for his patient, GM. The prescription was for a compounded cream containing ketamine, a Schedule III controlled substance. Dr. Singh stated that he wrote a prescription on April 1, 2015, for 200 grams of the cream for a one-month supply with one additional refill. He informed the Board that the CURES report concerning his prescription indicated respondent Pharmacy dispensed the medication to GM every three to five days. Dr. Singh was concerned for the safety of his patient, as the improper use of ketamine, even topically, can be harmful.

72. The Board generated a CURES report for GM. The report indicated that the prescription had been dispensed to GM on a monthly basis until April 2, 2015, when prescriptions containing ketamine were dispensed about every three to five days. According to the CURES report, the dispensed quantities of ketamine were reported as “0.”

73. At their July 22, 2015 inspection, the inspectors discussed GM’s prescription with respondent.

Respondent showed Inspector Nip the original April 1 handwritten prescription from Dr. Singh. It stated: “Compounding Cream: Gabapentin 10%, Lidocaine 10%, Clonidine 0.5%, Cyclobenzaprine 2%, Flurbiprofen 2%, Ketamine 2%, use 1 gm locally tid prn X 4 wks, Qty 200 grams” with one refill. It was not written on a California Security Prescription form. Respondent’s records included a prescription label, indicating that respondent filled the prescription on April 2, 2015. Respondent did not tell Nip, and the records he produced for her did not state, that he had taken a verbal prescription from Dr. Singh for the medication.

Respondent told the inspectors that, prior to April 2015, GM’s insurance company paid for the prescribed 200 grams of compounded cream that he dispensed monthly. In April 2015, respondent stated, GM’s insurance company would only reimburse for 20 grams at a time. Instead of dispensing 20 grams every few days, which would have been an inconvenience for GM, respondent decided to dispense all 200 grams at once to GM, in accordance with the prescription, but bill the insurance company on a recurring cycle of 20 grams every few days until the cost of the full 200 grams was reimbursed. On his CURES report, respondent reported dispensing 20 grams of the compounding cream every few days.
Respondent cannot explain why the CURES report indicates "0" for ketamine. He suggests that the CURES report may have defaulted to zero because it was such a small portion of the reported 20 grams of compounding cream. No evidence supports respondent’s speculation on this point, and it is unpersuasive. Under the law, it is the reporter’s obligation to state the quantity of controlled substance dispensed. It is concluded that respondent reported to CURES that he dispensed "0" ketamine with this prescription, a report that was not accurate.

74. Shortly before hearing in March 2016, respondent claimed for the first time that he obtained a verbal order from Dr. Singh for the April 2015 prescription. He produced a prescription form dated April 2, 2015, with the same formula as Dr. Singh’s April 1 prescription, but this document is in respondent’s handwriting and it contains the legend “VORB [Verbal Order Read Back] 4/2/15.” Respondent testified that he called Dr. Singh’s office on April 2 and obtained the prescription over the phone from “Jessica.” According to respondent, the VORB prescription form should have been stapled to the written prescription filled out by Dr. Singh, but it “got separated.” He states that it was in the same folder as Dr. Singh’s prescription, but both he and the inspector “overlooked it.” Respondent never mentioned the VORB prescription to the inspectors.

75. The evidence fails to establish that respondent filled GM’s prescription from a verbal order. Respondent did not claim that he had done so when Nip first inquired about the prescription, and the records he produced at that time did not indicate that the prescription was filled from a verbal order. On the contrary, the label indicated the prescription was filled from Dr. Singh’s written prescription. No independent evidence corroborates respondent’s belated claim that he filled the prescription from a verbal order.

76. Respondent’s medication profile of GM was inaccurate. Respondent dispensed 200 grams of the cream prescribed by Dr. Singh on April 2, 2015, and on May 7, 2015. GM’s medication profile, however, incorrectly stated that 20 grams of the cream were dispensed on April 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, and May 3, 8, 11, 14, 17, 20, 23, 26 and 29.

77. Respondent reported to CURES incorrect prescription numbers, dispensing dates and quantity of dispensed ketamine to GM between April 2 and May 7. The correct information is that respondent dispensed prescription number 132454 on April 2 in the quantity of 200 grams (4 grams of ketamine), and dispensed prescription number 132966 on May 7 in the quantity of 200 grams (4 grams of ketamine). Respondent reported to CURES that he dispensed prescription number 132454 on April 2, 5, 14, and 17; prescription number 132966 on April 20 and 23; prescription number 131095 on April 23 and 26; prescription number 132966 on April 26 and 29; prescription number 131095 on April 30; prescription number 132966 on May 8 and 11; prescription number 133158 on May 14 and 17; and prescription number 133549 on June 12. Respondent incorrectly reported to CURES that the quantity of ketamine dispensed was "0."

78. Respondent acknowledges that GM’s medication profile contains “inconsistencies,” but he does not acknowledge that the medication profile is inaccurate.
Respondent admits that the CURES report is not accurate as to the dates on which the medication was dispensed and as to the quantity of ketamine, but he does not agree that he submitted inaccurate information to CURES, and he believes the CURES report is accurate. Respondent’s parsing of the medication profile and the CURES report demonstrates a lack of insight into his reporting obligations, and his testimony on these points is unpersuasive.

FIRST ALLEGED CAUSE TO REVOKE RESPONDENT PHARMACY’S PROBATION

79. As noted above, Condition 9 of respondent Pharmacy’s probation requires the pharmacy to give notice of its probationary status to employees. The evidence fails to establish that respondent Pharmacy violated this condition, by reason of the matters set forth in Findings 40 through 43.

80. As noted above, Condition 11 of respondent Pharmacy’s probation requires the pharmacy to prominently post a probation notice in a place conspicuous and readable to the public. Respondent Pharmacy violated this condition, by reason of the matters set forth in Findings 48 through 54.

FIRST ALLEGED CAUSE TO REVOKE RESPONDENT’S PROBATION

81. As noted above, Condition 21 of respondent’s probation prohibits respondent from supervising interns and from assuming unauthorized supervision responsibilities. Respondent violated this condition, by reason of the matters set forth in Findings 44 through 47.

Other matters

82. Respondent’s conduct during the investigation of this case is marked by inconsistent statements, by evasion of the requirements of his probation, by improbable and untruthful statements to investigators, and by the belated production of exculpatory documents that lack credibility. Respondent is not a trustworthy licensee.

83. Senior Inspector Ignacio testified that respondent did not have a good understanding of his responsibilities as the pharmacist-in-chief of a compounding pharmacy, and that he was not acting in a manner consistent with public health. Ignacio and Nip tried to bring him into compliance, but respondent did not accept responsibility for any misconduct and was not willing to comply with the inspectors’ recommendations. In Ignacio’s opinion, respondent’s operation of respondent Pharmacy posed a significant risk to the public. Ignacio’s testimony on these points is consistent with the evidence, and is credible and persuasive.

Cost recovery

84. The Board has incurred costs of $29,054.25 in its investigation and enforcement of this case. Of that amount, $9,039.25 is for investigation costs incurred by the
Board, and $20,015 represents billings by the Department of Justice of attorney and paralegal services. These charges are supported by declarations that comply with section 1042, title 1, of the California Code of Regulations. In the absence of any evidence or argument to the contrary, these costs are found to be reasonable.

LEGAL CONCLUSIONS

1. The standard of proof applied in making the factual findings set forth above is clear and convincing evidence to a reasonable certainty.

2. The Board may take disciplinary action against a licensee who has engaged in unprofessional conduct. (Bus. & Prof. Code, § 4301.) The term “unprofessional conduct” is defined to include “[v]iolating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiracy to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the [B]oard or by any other state or federal regulatory agency.” (§ 4301, subd. (o).)

First cause for discipline (exceeding pharmacist/technician ratio)

3. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 12 through 20.

Second cause for discipline (dispensing drugs in incorrectly labeled container)

4. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 22 through 26.

Third cause for discipline (failure to label prescription container with name of manufacturer)

5. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 22 through 26.

Fourth cause for discipline (alleged failure to implement quality assurance)

6. Cause was not established to take disciplinary action against respondents, by reason of the matters set forth in Findings 27 through 32.

---

2 Statutory references are to the Business and Professions Code, unless otherwise stated.
Fifth cause for discipline (failure to conduct biennial inventory)

7. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 33 through 39.

Sixth cause for discipline (alleged failure to notify employees of probation status)

8. Cause was not established to take disciplinary action against respondents, by reason of the matters set forth in Findings 40 through 43.

Seventh cause for discipline (supervision of interns)

9. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 44 through 46.

Eighth cause for discipline (failure to properly post Notice of Probation)

10. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 48 through 54.

Ninth cause for discipline (compounding and dispensing misbranded drug product)

11. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 55 through 63.

Tenth cause for discipline (purchasing and dispensing domperidone)

12. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 55 through 63.

Eleventh cause for discipline (alleged dispensing of adulterated drugs)

13. Cause was not established to take disciplinary action against respondents, by reason of the matters set forth in Findings 64 through 67.

Twelfth cause for discipline (dispensing controlled substance on a prescription not made on a California Security Prescription form)

14. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 68 through 78.

Thirteenth cause for discipline (failure to maintain accurate patient medication profile)

15. Cause exists under section 4301, subdivision (o), to take disciplinary action against respondents by reason of the matters set forth in Findings 68 through 78.

20
Fourteenth cause for discipline (reporting inaccurate information to CURES)

16. Cause exists under section 4301, subdivision (c), to take disciplinary action against respondents by reason of the matters set forth in Findings 68 through 78.

First cause to revoke respondent Pharmacy's probation

17. Cause was not established to revoke the probation of respondent Pharmacy for failing to notify employees of its probationary status, by reason of the matters stated in Findings 40 through 43, and 79.

18. Cause exists to revoke respondent Pharmacy's probation for failing to properly post a Notice of Probation, by reason of the matters set forth in Findings 48 through 54, and 80.

First cause to revoke respondent's probation

19. Cause exists to revoke respondent's probation due to his supervision of interns, by reason of the matters set forth in Findings 44 through 46, and 81.

Disciplinary considerations

20. Despite serious deficiencies in his practice, respondent was granted a period of probation beginning in August 2013. Probation was respondent's opportunity to demonstrate that he can practice in compliance with legal requirements. Investigation of his practice, however, between March 2014 and July 2015 revealed more violations: respondent's prescription records and containers did not comply with legal requirements; respondent failed to timely perform a controlled substance inventory; he maintained an inaccurate patient medication profile for GM; he submitted inaccurate information to CURES concerning GM's prescription; and he compounded and dispensed domperidone under circumstances that presented a risk of serious harm to female patients. The investigation also revealed violations of respondents' probation: respondent repeatedly tried to evade the requirement that he post a Notice of Probation in a place where it would be conspicuous and readable by his customers, and he supervised interns despite being prohibited from doing so.

There is no reason to believe that respondents will conform to legal requirements in the future. In addition to demonstrating further violations of pharmacy law, the evidence established that respondent is not a trustworthy licensee. He made inconsistent statements to the inspectors about Martin's absence on June 3; he objected to unannounced inspections when he was found to have exceeded the pharmacist/technician ratio; he refused to post the Notice of Probation in a conspicuous place; he falsely told the inspectors that he used food coloring to color-code capsules; he unpersuasively maintained that his patient medication profile and CURES reports regarding GM were accurate; and he belatedly produced at hearing three documents—a purported biennial inventory, a purported telephone prescription for GM, and a purported email to Inspector Nip—that lack credibility. With minor
exceptions, respondent does not acknowledge that he engaged in unprofessional conduct but, instead, defends his conduct. It would be contrary to the public interest to allow respondents to retain their licenses, even on a probationary basis.

21. Accordingly,

a. Respondent Pharmacy’s probation will be revoked, the stay order will be set aside, and the revocation of respondent Pharmacy’s license will be imposed pursuant to Legal Conclusions 18 and 20.

b. Respondent Pharmacy’s license will be revoked pursuant to Legal Conclusions 3, 4, 5, 7, 9, 10, 11, 12, 14, 15, 16 and 20.

c. Respondent’s probation will be revoked, the stay order will be set aside, and the revocation of respondent’s registered pharmacist license will be imposed pursuant to Legal Conclusions 19 and 20.

d. Respondent’s registered pharmacist license will be revoked pursuant to Legal Conclusions 3, 4, 5, 7, 9, 10, 11, 12, 14, 15, 16 and 20.

Cost recovery

22. Section 125.3 provides that a licentiate found to have violated the licensing laws may be ordered to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

As set forth in Finding 84, it was established that complainant has incurred $29,054.25 in actual costs in connection with the investigation and enforcement of this matter.

23. The case of Zuckerman v. Board of Chiropractic Examiners (2002) 29 Cal.4th 32 sets forth certain standards by which a licensing board must exercise its discretion to reduce or eliminate cost awards to ensure that licensees with potentially meritorious claims are not deterred from exercising their right to an administrative hearing. Those standards include whether the licensee has been successful at hearing in getting the charges dismissed or reduced, the licensee’s good faith belief in the merits of his position, whether the licensee has raised a colorable challenge to the proposed discipline, the financial ability of the licensee to pay, and whether the scope of the investigation was appropriate to the alleged misconduct.

24. Respondents successfully defended three of the 14 alleged causes for discipline. In addition, it is recognized that respondent Pharmacy, whose license is revoked by this decision, is the sole source of income for respondent and his family. Accordingly, complainant’s cost recovery will be reduced by approximately 25 percent, to $21,700.
ORDER

1. The probation granted to respondent ERA Pharmacy Inc., dba Santa Clara Drug "The Compounding Shop," in Case No. 4842 is revoked, the stay order is set aside, and the revocation of Retail Pharmacy License Number PHY 51229 is imposed.

2. Retail Pharmacy License Number PHY 51229, issued to ERA Pharmacy Inc., dba Santa Clara Drug "The Compounding Shop," is revoked.

3. The probation granted to respondent Vishal B. Purohit in Case No. 4842, is revoked, the stay order is set aside, and the revocation of Registered Pharmacist License Number RPH 62617 is imposed.

4. Registered Pharmacist License Number RPH 62617, issued to respondent Vishal B. Purohit, is revoked.

5. Respondents shall pay the Board of Pharmacy its costs of investigation and enforcement in the amount of $21,700. Respondents may pay these costs in installments according to a payment plan approved by the Board.

DATED: May 13, 2016

[Signature]

DAVID L. BENJAMIN
Administrative Law Judge
Office of Administrative Hearings
In the Matter of the Accusation and Petition to Revoke Probation Against:

SANTA CLARA DRUG “THE COMPOUNDING SHOP”
2453 Forest Avenue
San Jose, CA 95128

Retail Pharmacy License No. PHY 51229

VISHAL B. PUROHIT
2453 Forest Avenue
San Jose, CA 95128

Registered Pharmacist License No. RPH 62617

Respondents.

Complainant alleges:

PARTIES

1. Virginia Herold (Complainant) brings this First Amended Accusation and Petition to Revoke Probation solely in her official capacity as the Executive Officer of the Board of Pharmacy (Board), Department of Consumer Affairs.

2. On or about March 8, 2013, the Board issued Retail Pharmacy License Number PHY 51229 to ERA Pharmacy Inc., dba Santa Clara Drug "The Compounding Shop" (Respondent Pharmacy). The Retail Pharmacy License was in full force and effect at all times relevant to the
charges brought herein and will expire on March 1, 2016, unless renewed.

3. On or about July 28, 2009, the Board issued Registered Pharmacist License Number RPH 62617 to Vishal B. Purohit (Respondent Pharmacist). The Registered Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on November 30, 2016, unless renewed.

4. In a disciplinary action entitled "In the Matter of the Accusation Against: Santa Clara Drug "The Compounding Shop" and Vishal B. Purohit," Case No. 4842, the Board of Pharmacy issued a Decision and Order effective August 30, 2013, in which Respondent Pharmacy’s License and Respondent Pharmacist’s License were revoked. However, the revocations were stayed and Respondents’ Licenses were placed on probation for five (5) years with certain terms and conditions. A copy of that Decision and Order is attached as Exhibit A and is incorporated by reference.

**JURISDICTION**

5. This First Amended Accusation and Petition to Revoke Probation is brought before the Board, under the authority of the following laws. All section references are to the Business and Professions Code ("Code") unless otherwise indicated.

6. Code section 4011 provides that the Board shall administer and enforce both the Pharmacy Law [Bus. & Prof. Code, § 4000 et seq.] and the Uniform Controlled Substances Act [Health & Safety Code, § 11000 et seq.].

7. Code section 4300 provides that every license issued by the Board may be suspended or revoked.

8. Code section 4300.1 states:

   "The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license."

///
STATUTORY AND REGULATORY PROVISIONS

9. Code section 4076 states:
"(a) A pharmacist shall not dispense any prescription except in a container that meets the requirements of state and federal law and is correctly labeled with all of the following:
"...

"(11)(A) Commencing January 1, 2006, the physical description of the dispensed medication, including its color, shape, and any identification code that appears on the tablets or capsules, except as follows:
"(i) Prescriptions dispensed by a veterinarian.
"(ii) An exemption from the requirements of this paragraph shall be granted to a new drug for the first 120 days that the drug is on the market and for the 90 days during which the national reference file has no description on file.
"(iii) Dispensed medications for which no physical description exists in any commercially available database.
"...

10. Code section 4077 states:
"(a) Except as provided in subdivisions (b) and (c) of this section, no person shall dispense any dangerous drug upon prescription except in a container correctly labeled with the information required by Section 4076.
"...

11. Code section 4115 states:
"(a) A pharmacy technician may perform packaging, manipulative, repetitive, or other nondiscretionary tasks, only while assisting, and while under the direct supervision and control of a pharmacist. The pharmacist shall be responsible for the duties performed under his or her supervision by a technician.
"...

"(f)(1) A pharmacy with only one pharmacist shall have no more than one pharmacy technician performing the tasks specified in subdivision (a). The ratio of pharmacy technicians

FIRST AMENDED ACCUSATION AND PETITION TO REVOKE PROBATION
performing the tasks specified in subdivision (a) to any additional pharmacist shall not exceed 2:1, except that this ratio shall not apply to personnel performing clerical functions pursuant to Section 4116 or 4117. This ratio is applicable to all practice settings, except for an inpatient of a licensed health facility, a patient of a licensed home health agency, as specified in paragraph (2), an inmate of a correctional facility of the Department of Corrections and Rehabilitation, and for a person receiving treatment in a facility operated by the State Department of State Hospitals, the State Department of Developmental Services, or the Department of Veterans Affairs.

"..."

12. Code section 4169 states:

"(a) A person or entity shall not do any of the following:

"...

"(2) Purchase, trade, sell, or transfer dangerous drugs that the person knew or reasonably should have known were adulterated, as set forth in Article 2 (commencing with Section 111250) of Chapter 6 of Part 5 of Division 104 of the Health and Safety Code.

"(3) Purchase, trade, sell, or transfer dangerous drugs that the person knew or reasonably should have known were misbranded, as defined in Section 111335 of the Health and Safety Code.

"..."

13. Code section 4301 states:

"The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

"...

"(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency.

"..."
14. Health & Safety Code section 11255 states:

"Any drug or device is adulterated if it has been produced, prepared, packed, or held under conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health."

15. Health & Safety Code section 11335 states:

"Any drug or device is misbranded if its labeling or packaging does not conform to the requirements of Chapter 4 (commencing with Section 110290)."

16. Health & Safety Code section 11400 states:

"Any drug or device is misbranded if it is dangerous to health when used in the dosage, or with the frequency or duration prescribed, recommended, or suggested in its labeling."

17. Health & Safety Code section 11440 states:

"It is unlawful for any person to manufacture, sell, deliver, hold, or offer for sale any drug or device that is misbranded."

18. Health & Safety Code section 1164 states, in pertinent part:

"Except as provided in Section 1167, no person shall prescribe a controlled substance, nor shall any person fill, compound, or dispense a prescription for a controlled substance, unless it complies with the requirements of this section.

"(a) Each prescription for a controlled substance classified in Schedule II, III, IV, or V, except as authorized by subdivision (b), shall be made on a controlled substance prescription form as specified in Section 1162.1 and shall meet the following requirements:

"...

19. Health & Safety Code section 1165 states, in pertinent part:

"...

"(d) For each prescription for a Schedule II, Schedule III, or Schedule IV controlled substance, as defined in the controlled substances schedules in federal law and regulations, specifically Sections 1308.12, 1308.13, and 1308.14, respectively, of Title 21 of the Code of Federal Regulations, the dispensing pharmacy, clinic, or other dispenser shall report the following information to the Department of Justice as soon as reasonably possible, but not more than seven
days after the date a controlled substance is dispensed, in a format specified by the Department of
Justice:

"...

"(3) Pharmacy prescription number, license number, NPI number, and federal controlled
substance registration number.

"...

"(5) Quantity of the controlled substance dispensed

"...

"(10) Date of dispensing of the prescription.

"..."

20. 21 U.S.C. § 352 states:

"A drug or device shall be deemed to be misbranded—

"...

"(f) Directions for use and warnings on label

Unless its labeling bears (1) adequate directions for use; and (2) such adequate warnings
against use in those pathological conditions or by children where its use may be dangerous to
health, or against unsafe dosage or methods or duration of administration or application, in such
manner and form, as are necessary for the protection of users, except that where any requirement
of clause (1) of this paragraph, as applied to any drug or device, is not necessary for the protection
of the public health, the Secretary shall promulgate regulations exempting such drug or device
from such requirement. Required labeling for prescription devices intended for use in health care
facilities or by a health care professional and required labeling for in vitro diagnostic devices
intended for use by health care professionals or in blood establishments may be made available
solely by electronic means, provided that the labeling complies with all applicable requirements of
law, and that the manufacturer affords such users the opportunity to request the labeling in paper
form, and after such request, promptly provides the requested information without additional cost.

"...

///
21. California Code of Regulations, Title 16, section 1707.1 states:

"(a) A pharmacy shall maintain medication profiles on all patients who have prescriptions filled in that pharmacy except when the pharmacist has reasonable belief that the patient will not continue to obtain prescription medications from that pharmacy.

"(1) A patient medication record shall be maintained in an automated data processing or manual record mode such that the following information is readily retrievable during the pharmacy's normal operating hours.

"...

"(B) For each prescription dispensed by the pharmacy:

"1. The name, strength, dosage form, route of administration, if other than oral, quantity and directions for use of any drug dispensed;

"...

"3. The date on which a drug was dispensed or refilled;

"...

"5. The information required by section 1717.

"...

22. California Code of Regulations, Title 16, section 1707.5 states:\n
"(a) Labels on drug containers dispensed to patients in California shall conform to the following format:

"(1) Each of the following items shall be clustered into one area of the label that comprises at least 50 percent of the label. Each item shall be printed in at least a 10 point sans serif typeface, and listed in the following order:

"(A) Name of the patient

///

---

1 Regulation amended on April 1, 2015 to read, in pertinent part, "(a) Labels on drug containers dispensed to patients in California shall conform to the following format:

"(1) Each of the following items, and only these four items, shall be clustered into one area of the label that comprises at least 50 percent of the label. Each item shall be printed in at least a 12-point sans serif typeface, and listed in the following order:..."
(B) Name of the drug and strength of the drug. For the purposes of this section, "name of the drug" means either the manufacturer's trade name of the drug, or the generic name and the name of the manufacturer.

"...

23. California Code of Regulations, Title 16, section 1717 states:

"...

"(b) In addition to the requirements of Business and Professions Code section 4040, the following information shall be maintained for each prescription on file and shall be readily retrievable:

"...

"(3) If a prescription for a drug or device is refilled, a record of each refill, quantity dispensed, if different, and the initials or name of the dispensing pharmacist.

"...

24. California Code of Regulations, Title 16, section 1735.8 states:

"(a) Any pharmacy engaged in compounding shall maintain, as part of its written policies and procedures, a written quality assurance plan designed to monitor and ensure the integrity, potency, quality, and labeled strength of compounded drug products.

"...

"(c) The quality assurance plan shall include written standards for qualitative and quantitative integrity, potency, quality, and labeled strength analysis of compounded drug products. All qualitative and quantitative analysis reports for compounded drug products shall be retained by the pharmacy and collated with the compounding record and master formula.

"...

25. California Code of Regulations, Title 16, section 1773 states:

"(a) Unless otherwise directed by the Board in its sole discretion, any pharmacist who is serving a period of probation shall comply with the following conditions:

"(1) Obey all laws and regulations substantially related to the practice of Pharmacy;

"...
"(6) Not supervise any registered interns nor perform any of the duties of a preceptor;"

"..."

26. California Code of Regulations, Title 16, section 1774 states:

"(a) Unless otherwise directed by the Board, any pharmacy permit which is on probation to
the Board shall be subject to the following conditions:

"..."

"(4) Post or circulate notice of conditions of probation so that they are available to all
employees involved in pharmacy operations;

"..."

"(b) When the circumstances of the case so require, the Board may impose conditions of
probation in addition to those enumerated herein by the terms of its decision in an administrative
case or by stipulation of the parties."

27. 21 C.F.R. § 1304.11 states:

"..."

"(c) Biennial inventory date. After the initial inventory is taken, the registrant shall take a
new inventory of all stocks of controlled substances on hand at least every two years. The biennial
inventory may be taken on any date which is within two years of the previous biennial inventory
date.

"..."

COST RECOVERY

28. Code section 125.3 states, in pertinent part, that the Board may request the
administrative law judge to direct a licentiate found to have committed a violation or violations of
the licensing act to pay a sum not to exceed the reasonable costs of the investigation and
enforcement of the case.

///

///

///

///
FACTUAL BACKGROUND

29. On or about June 3, 2014, two Board Inspectors conducted a routine inspection at Respondent Pharmacy. They were met and assisted by Respondent Pharmacist. During the course of that inspection, the Inspector(s) found:

a. Three pharmacy technicians performing pharmacy technician duties when only Respondent Pharmacist was on duty;

b. Prescription containers in the “will call” area that were missing identification codes of the dispensed medications, drug manufacturer information, and contained medication from more than one manufacturer;

c. That Respondents did not provide records and documentation of qualitative and quantitative analysis for the pharmacy’s compounded drug preparations;

d. That the most recent biennial inventory of Schedule III to V controlled substances was completed on April 25, 2012;

e. That Respondent Pharmacy failed to inform employees of the its probation status;

f. That Respondent Pharmacist initialed prescriptions filled by an intern pharmacist and supervised activities performed by an intern pharmacist while he was the only pharmacist on duty;

30. On or about March 19, 2015, two Board Inspectors conducted a routine inspection at Respondent Pharmacy. They were met and assisted by Respondent Pharmacist. During the course of that inspection, the Inspector(s) found:

a. That the Notice of Probation was posted in a manner that made it unreadable;

b. That between approximately January 1, 2014 and February 28, 2015,

2 Respondent Pharmacy did not inform Pharmacist Intern SA, who obtained about 158 hours of pharmacy practice experience between February 26, 2014 and March 27, 2014, that the pharmacy was on probation or of the terms of probation. Similarly, Respondent Pharmacy did not inform volunteer Pharmacy Technician AS, who at the time had volunteered at Respondent Pharmacy two days per week since May 2014, about its probation status.

3 Respondent Pharmacist supervised the activities performed by intern pharmacist CS while he was the only pharmacist on duty.
Respondents compounded and dispensed prescriptions containing domperidone without having an 
FDA-approved Investigational New Drug application.

31. On or about July 22, 2015, two Board Inspectors conducted an inspection at 
Respondent Pharmacy. They were met and assisted by Respondent Pharmacist. During the course 
of that inspection, the Inspector(s) found:

a. That Respondents used non-edible color markers to mark compounded capsules 
that were to be consumed orally by patients;

b. That Respondents filled and dispensed controlled substances without 
prescriptions written on California Security Prescription forms;

c. That Respondents failed to maintain an accurate patient medication profile for 
patient GM4; and

d. That Respondents provided the Controlled Substance Utilization Review and 
evaluation System (CURES) with inaccurate information related to patient GM’s prescription 
numbers, dispensing dates, and quantity of controlled substance dispensed.

FIRST CAUSE FOR DISCIPLINE
(Exceeding Pharmacist to Technician Ratio)

32. Respondents are subject to disciplinary action under Code sections 4301, subdivision 
(o), and/or 4115, subdivision (a) and/or (f)(1) in that, as described in paragraph 29, above, 
Respondents exceeded the pharmacist to technician ratio.

SECOND CAUSE FOR DISCIPLINE
(Dispensing Dangerous Drugs in Incorrectly Labeled Container)

33. Respondents are subject to disciplinary action under Code sections 4301, subdivision 
(o), 4076, subdivision (a)(11)(A), and/or 4077 subdivision (a), in that, as described in paragraph 
29, above, Respondents dispensed drugs in incorrectly labeled containers.

///

4 Patient name withheld to maintain privacy.
THIRD CAUSE FOR DISCIPLINE
(Failure to Label Prescription Containers with Name of Manufacturer)

34. Respondents are subject to disciplinary action under Code section 4301, subdivision (o), and/or California Code of Regulations, title 16, section 1707.5, in that, as described in paragraph 29, above, Respondents failed to include the name of the generic drug manufacturer on prescription container labels.

FOURTH CAUSE FOR DISCIPLINE
(Failure to Implement Quality Assurance For Compounded Drug Products)

35. Respondents are subject to disciplinary action under Code section 4301, subdivision (o), and/or California Code of Regulations, title 16, section 1735.8, subdivision (c), in that, as described in paragraph 29, above, Respondents failed to demonstrate quality assurance in the form of qualitative and quantitative analysis of compounded drug preparations.

FIFTH CAUSE FOR DISCIPLINE
(Failure to Conduct Biennial Inventory)

36. Respondents are subject to disciplinary action under Code section 4301, subdivision (o), and/or 21 C.F.R. § 1304.11(c), in that, as described in paragraph 29, above, Respondents failed to conduct a biennial inventory within the required time frame.

SIXTH CAUSE FOR DISCIPLINE
(Failure to Comply with Conditions of Probation)

37. Respondent Pharmacy is subject to disciplinary action under Code section 4301, subdivision (o), and/or California Code of Regulations, title 16, section 1774, subdivision (a)(4), as related to Term and Condition 9 of the Probation Order in Case No. 4842 in that, as described in paragraph 29, above, Respondent Pharmacy did not inform a pharmacist intern and/or a pharmacy technician of its probation status.

SEVENTH CAUSE FOR DISCIPLINE
(Failure to Comply with Conditions of Probation)

38. Respondent Pharmacist is subject to disciplinary action under Code section 4301, subdivision (o), and/or California Code of Regulations, title 16, section 1773, subdivision (a)(6), as
related to Term and Condition 21 of the Probation Order in Case No. 4842, in that, as described in paragraph 29, above, Respondent Pharmacist supervised one or more intern pharmacists while Respondent Pharmacist was on probation.

EIGHTH CAUSE FOR DISCIPLINE

(Failure to Comply with Disciplinary Conditions of Probation Permit)

39. Respondents are subject to disciplinary action under Code section 4301, subdivision (o), and/or California Code of Regulations, title 16, section 1774, subdivision (b), in that, as described in paragraph 30, above, Respondents did not place the Notice of Probation in a visible space readable by the public.

NINTH CAUSE FOR DISCIPLINE

(Compounding and Dispensing Misbranded Drug Product)

40. Respondents are subject to disciplinary action under Code section 4301, subdivision (o), Health and Safety Code section 111400, Heath and Safety Code section 111440, and/or 21 U.S.C. § 352(f), in that, as described in paragraph 30, above, Respondents dispensed 48 prescriptions of compounded drug capsules containing domperidone without having an approved Investigational New Drug application on file.

TENTH CAUSE FOR DISCIPLINE

(Commission of Prohibited Acts)

41. Respondents are subject to disciplinary action under Code sections 4301, subdivision (o), and/or 4169, subdivision (a)(3), and Health and Safety Code section 11335, in that, as described in paragraph 30, above, Respondents purchased domperidone powder and dispensed 48 prescriptions of compounded drug capsules containing domperidone without having an approved Investigational New Drug application on file.

ELEVENTH CAUSE FOR DISCIPLINE

(Dispensing Adulterated Drugs)

42. Respondents are subject to disciplinary action under Code sections 4301, subdivision (o) and/or 4169, subdivision (a)(2) in conjunction with Health and Safety Code section 111255, in that, as described in paragraph 31, above, Respondents dispensed adulterated drugs when they
used non-edible color markers to mark compounded capsules that were to be orally consumed by patients.

**TWELFTH CAUSE FOR DISCIPLINE**

(Dispensed Controlled Substance Prescription Not Made on Security Form)

43. Respondents are subject to disciplinary action under Code section 4301, subdivision (o), and/or Health and Safety Code section 11164, subdivision (a), in that, as described in paragraph 31, above, Respondents filled and dispensed a prescription for a controlled substance that was not written on a California Security Prescription form.

**THIRTEENTH CAUSE FOR DISCIPLINE**

(Failed to Maintain Accurate Patient Medication Profile)

44. Respondents are subject to disciplinary action under Code section 4301, subdivision (o), and/or California Code of Regulations, title 16, sections 1707.1, subdivisions (a)(B)(1), (a)(B)(3), and (a)(B)(5), and 1717, subdivision (b)(3), in that, as described in paragraph 31, above, Respondents did not keep an accurate medication profile for patient GM.

**FOURTEENTH CAUSE FOR DISCIPLINE**

(Reported Inaccurate Information to CURES)

45. Respondents are subject to disciplinary action under Code section 4301, subdivision (o), and/or Health and Safety Code section 11165, subdivision (d)(3), (d)(5), and (d)(10), in that, as described in paragraph 31, above, Respondents reported the wrong prescription numbers, dispensing dates, and quantity of controlled substance dispensed for patient GM to CURES.

**PETITION TO REVOKE PROBATION**

**FIRST CAUSE TO REVOKE RESPONDENT PHARMACY'S PROBATION**

(Failure to Give Notice to Employees)

46. At all times after the effective date of the Decision and Order imposing probation of Respondent Pharmacy's license, Term and Condition 9 of that Order required that Respondent Pharmacy provide notice of its probationary status to its employees. Respondent Pharmacy violated this condition of probation.
47. At all times after the effective date of the Decision and Order imposing probation of Respondent Pharmacy's license, Term and Condition 11 of that Order required that Respondent Pharmacy to prominently post a probation notice in a place conspicuous and readable to the public. Respondent Pharmacy violated this condition of probation.

FIRST CAUSE TO REVOKE RESPONDENT PHARMACIST'S PROBATION

(Engaged in Supervision)

48. At all times after the effective date of the Decision and Order imposing probation on Respondent Pharmacist's license, Term and Condition 21 of that Order prohibited Respondent from supervising interns and from assuming unauthorized supervision responsibilities. Respondent Pharmacist violated this condition of probation.

OTHER MATTERS – EXTENSION OF PROBATION

49. At all times after the effective date of the Decision and Order imposing probation on Respondents' Licenses, Terms and Conditions 12 and 28 of that Order provided:

Violation of Probation.

If respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended, until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed. If respondent violates probation in any respect, the board, after giving respondent notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed.

If a petition to revoke probation or an accusation is filed against respondent during probation, the Board shall have continuing jurisdiction, and the period of probation shall be extended until the petition to revoke probation or accusation is heard and decided.

50. Pursuant to the operation of Terms and Conditions 12 and 28 of the probation order applicable to Respondents' Licenses in Case No. 4248, probation is automatically extended by the filing hereof, and/or by Respondents' failure to comply with the terms and conditions of probation, until such time as this First Amended Accusation and Petition to Revoke Probation is heard and decided, or until the Board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation.

///

///

FIRST AMENDED ACCUSATION AND PETITION TO REVOKE PROBATION
PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters alleged in this First Amended Accusation and Petition to Revoke Probation, and that following the hearing, the Board of Pharmacy issue a decision:

1. Revoking or suspending Retail Pharmacy License Number PHY 51229, issued to ERA Pharmacy Inc., dba Santa Clara Drug "The Compounding Shop" (Respondent Pharmacy);
2. Revoking or suspending Registered Pharmacist License Number RPH 62617, issued to Vishal B. Purohit (Respondent Pharmacist);
3. Revoking the probation that was granted by the Board of Pharmacy in Case No. 4842 and imposing the disciplinary order that was stayed thereby revoking Retail Pharmacy License Number PHY 51229 issued to Respondent Pharmacy;
4. Revoking the probation that was granted by the Board of Pharmacy in Case No. 4842 and imposing the disciplinary order that was stayed thereby revoking Registered Pharmacist License Number RPH 62617 issued to Respondent Pharmacist;
5. Ordering Respondents to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3; and
6. Taking such other and further action as deemed necessary and proper.

DATED: 1/14/16

VIRGINIA HAROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant
BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the Accusation Against:

SANTA CLARA DRUG "THE
COMPOUNDING SHOP"
2453 Forest Avenue
San Jose, CA 95128

Retail Pharmacy License No. PHY 51229

VISHAL B. PUROHIT
2453 Forest Avenue
San Jose, CA 95128

Registered Pharmacist License No. RPH 62617

Respondents.

Case No. 4842

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This decision shall become effective on August 30, 2013.

It is so ORDERED on August 30, 2013.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By

STANLEY C. WEISSER
Board President
BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

In the Matter of the Accusation Against:

SANTA CLARA DRUG "THE
COMPOUNDING SHOP"
2453 Forest Avenue
San Jose, CA 95128

Retail Pharmacy License No. PHY 51229

VISHAL B. PUROHIT
2453 Forest Avenue
San Jose, CA 95128

Registered Pharmacist License No. RPH 62617

Respondents.

Case No. 4842

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER

IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-entitled proceedings that the following matters are true:

PARTIES

1. Virginia Herold (Complainant) is the Executive Officer of the Board of Pharmacy (Board), Department of Consumer Affairs. She brought this action solely in her official capacity and is represented in this matter by Kamala D. Harris, Attorney General of the State of California, by Rosailda Perez, Deputy Attorney General.

2. Respondent Santa Clara Drug, "The Compounding Shop" (Respondent Pharmacy) and Respondent Vishal B. Purohit (Respondent Pharmacist) are represented in this proceeding by

Attorneys for Complainant

Attorneys for Respondents.
attorney Herbert L. Weinberg, whose address is: 1800 Century Park East, 8th Floor, Los Angeles, CA 90067-1501.

3. On or about March 8, 2013, the Board issued Retail Pharmacy License No. PHY 51229 to ERA Pharmacy, Inc., dba Santa Clara Drug, “The Compounding Shop.” The Retail Pharmacy License was in full force and effect at all times relevant to the charges brought in Accusation No. 4842 and will expire on September 4, 2013, unless renewed.

4. On or about July 28, 2009, the Board of Pharmacy issued Registered Pharmacist License No. RPH 62617 to Vishal B. Purohit. The Registered Pharmacist License was in full force and effect at all times relevant to the charges brought in Accusation No. 4842 and will expire on November 30, 2014, unless renewed.

JURISDICTION

5. Accusation No. 4842 was filed before the Board of Pharmacy (Board), Department of Consumer Affairs, and is currently pending against Respondents. The Accusation and all other statutorily required documents were properly served on Respondents on July 26, 2013. Respondents timely filed their Notice of Defense contesting the Accusation.

6. A copy of Accusation No. 4842 is attached as exhibit A and incorporated herein by reference.

ADVICEMENT AND WAIVERS

7. Respondents have carefully read, fully discussed with counsel, and understand the charges and allegations in Accusation No. 4842. Respondents have also carefully read, fully discussed with counsel, and understand the effects of this Stipulated Settlement and Disciplinary Order.

8. Respondents are fully aware of their legal rights in this matter, including the right to a hearing on the charges and allegations in the Accusation; the right to be represented by counsel at its own expense; the right to confront and cross-examine the witnesses against them; the right to present evidence and to testify on its own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California
Administrative Procedure Act and other applicable laws.

9. Respondents voluntarily, knowingly, and intelligently waive and give up each and every right set forth above.

10. Respondent Pharmacy agrees to withdraw its application for a sterile pharmacy compounding license it filed with the Board on or about November 10, 2012, and that is currently pending with the Board.

CULPABILITY

11. Respondents admit the truth of each and every charge and allegation in Accusation No. 4842.

12. Respondent Pharmacy agrees that its Retail Pharmacy License is subject to discipline and agrees to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

13. Respondent Pharmacist agrees that his Registered Pharmacist License is subject to discipline and agrees to be bound by the Board's probationary terms as set forth in the Disciplinary Order below.

CONTINGENCY

14. This stipulation shall be subject to approval by the Board of Pharmacy. Respondents understand and agree that counsel for Complainant and the staff of the Board of Pharmacy may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondent or its counsel. By signing the stipulation, Respondents understand and agree that they may not withdraw its agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.

15. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including Portable Document Format (PDF) and facsimile signatures thereto, shall have the same force and effect as the originals.
16. This Stipulated Settlement and Disciplinary Order is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.

17. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

**DISCIPLINARY ORDER AS TO RESPONDENT PHARMACY**

IT IS HEREBY ORDERED that Retail Pharmacy License No. PHY 51229, issued to Respondent Pharmacy, is revoked. However, the revocation is stayed and Respondent Pharmacy is placed on probation for five (5) years on the following terms and conditions:

1. **Obey All Laws**

   Respondent Pharmacy shall obey all state and federal laws and regulations.

   Respondent Pharmacy shall report any of the following occurrences to the board, in writing, within seventy-two (72) hours of such occurrence:

   • an arrest or issuance of a criminal complaint for violation of any provision of the Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
   • a plea of guilty or nolo contendere in any state or federal criminal proceeding to any criminal complaint, information or indictment
   • a conviction of any crime
   • discipline, citation, or other administrative action filed by any state or federal agency which involves respondent's Retail Pharmacy License No. PHY 51229 or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging for any drug, device or controlled substance.

   Failure to timely report any such occurrence shall be considered a violation of probation.
2. **Report to the Board**

Respondent Pharmacy shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, Respondent Pharmacy shall state in each report, under penalty of perjury, whether there has been compliance with all the terms and conditions of probation. If, pursuant to term and condition 33, below, Respondent Pharmacist has retained a consulting pharmacist approved by the board or its designee, then any written report submitted to the board pursuant to this provision shall also be executed under penalty of perjury, by the approved consulting pharmacist. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be automatically extended until such time as the final report is made and accepted by the board.

3. **Interview with the Board**

Upon receipt of reasonable prior notice, Respondent Pharmacy shall appear in person for interviews with the board or its designee, at such intervals and locations as are determined by the board or its designee. Failure to appear for any scheduled interview without prior notification to board staff, or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.

4. **Cooperate with Board Staff**

Respondent Pharmacy shall cooperate with the board's inspection program and with the board's monitoring and investigation of respondent's compliance with the terms and conditions of their probation. Failure to cooperate shall be considered a violation of probation.

5. **Reimbursement of Board Costs**

As a condition precedent to successful completion of probation, Respondent Pharmacy shall be jointly and severally liable with Respondent Pharmacist for payment of the Board's costs of investigation and prosecution in the amount of $10,739.00. Respondent Pharmacy shall make said payments following a payment plan approved by the board or its designee. There shall be no
deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by Respondent Pharmacy shall not relieve respondent of its responsibility to reimburse the board its costs of investigation and prosecution.

6. **Probation Monitoring Costs**

   Respondent Pharmacy shall pay any costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

7. **Status of License**

   Respondent Pharmacy shall, at all times while on probation, maintain current licensure with the board. If Respondent Pharmacy submits an application to the board, and the application is approved, for a change of location, change of permit or change of ownership, the board shall retain continuing jurisdiction over the license, and the respondent shall remain on probation as determined by the board. Failure to maintain current licensure shall be considered a violation of probation.

   If Respondent Pharmacy's license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof or otherwise, upon renewal or reapplication Respondent Pharmacy's license shall be subject to all terms and conditions of this probation not previously satisfied.

8. **License Surrender While on Probation/Suspension**

   Following the effective date of this decision, should Respondent Pharmacy discontinue business, Respondent Pharmacy may tender the premises license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, Respondent Pharmacy will no longer be subject to the terms and conditions of probation.

   Upon acceptance of the surrender, Respondent Pharmacy shall relinquish the premises wall
and renewal license to the board within ten (10) days of notification by the board that the
surrender is accepted. Respondent Pharmacy shall further submit a completed Discontinuance of
Business form according to board guidelines and shall notify the board of the records inventory
transfer.

Respondent Pharmacy shall also, by the effective date of the decision accepting the
surrender, arrange for the continuation of care for ongoing patients of the pharmacy by, at
minimum, providing a written notice to ongoing patients that specifies the anticipated closing
date of the pharmacy and that identifies one or more area pharmacies capable of taking up the
patients' care, and by cooperating as may be necessary in the transfer of records or prescriptions
for ongoing patients. Within five days of its provision to the pharmacy's ongoing patients,
Respondent Pharmacy shall provide a copy of the written notice to the board. For the purposes of
this provision, "ongoing patients" means those patients for whom the pharmacy has on file a
prescription with one or more refills outstanding, or for whom the pharmacy has filled a
prescription within the preceding sixty (60) days.

Respondent Pharmacy may not apply for any new licensure from the board for three (3)
years from the effective date of the surrender. Respondent Pharmacy shall meet all requirements
applicable to the license sought as of the date the application for that license is submitted to the
board.

Respondent Pharmacy further stipulates that it shall reimburse the board for its costs of
investigation and prosecution prior to the acceptance of the surrender.

9. Notice to Employees

Respondent Pharmacy shall, upon or before the effective date of this decision, ensure that
all employees involved in permit operations are made aware of all the terms and conditions of
probation, either by posting a notice of the terms and conditions, circulating such notice, or both.
If the notice required by this provision is posted, it shall be posted in a prominent place and shall
remain posted throughout the probation period. Respondent Pharmacy shall ensure that any
employees hired or used after the effective date of this decision are made aware of the terms and
conditions of probation by posting a notice, circulating a notice, or both. Additionally,
Respondent Pharmacy shall submit written notification to the board, within fifteen (15) days of the effective date of this decision, that this term has been satisfied. Failure to submit such notification to the board shall be considered a violation of probation.

"Employees" as used in this provision includes all full-time, part-time, volunteer, temporary and relief employees and independent contractors employed or hired at any time during probation.

10. Owners and Officers: Knowledge of the Law

Respondent Pharmacy shall provide, within thirty (30) days after the effective date of this decision, signed and dated statements from its owners, including any owner or holder of ten percent (10%) or more of the interest in respondent or Respondent Pharmacy’s stock, and any officer, stating under penalty of perjury that said individuals have read and are familiar with state and federal laws and regulations governing the practice of pharmacy. The failure to timely provide said statements under penalty of perjury shall be considered a violation of probation.

11. Posted Notice of Probation

Respondent Pharmacy shall prominently post a probation notice provided by the board in a place conspicuous and readable to the public. The probation notice shall remain posted during the entire period of probation.

Respondent Pharmacy shall not, directly or indirectly, engage in any conduct or make any statement which is intended to mislead or is likely to have the effect of misleading any patient, customer, member of the public, or other person(s) as to the nature of and reason for the probation of the licensed entity.

Failure to post such notice shall be considered a violation of probation.

12. Violation of Probation

If Respondent Pharmacy has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent license, and probation shall be automatically extended until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.
If Respondent Pharmacy violates probation in any respect, the board, after giving
Respondent Pharmacy notice and an opportunity to be heard, may revoke probation and carry out
the disciplinary order that was stayed. Notice and opportunity to be heard are not required for
those provisions stating that a violation thereof may lead to automatic termination of the stay
and/or revocation of the license. If a petition to revoke probation or an accusation is filed against
Respondent Pharmacy during probation, the board shall have continuing jurisdiction and the
period of probation shall be automatically extended until the petition to revoke probation or
accusation is heard and decided.

13. Completion of Probation

Upon written notice by the board or its designee indicating successful completion of
probation, Respondent Pharmacy's license will be fully restored.

14. Restricted Practice

Respondent Pharmacy shall not prepare, oversee or participate in the preparation of
injectable sterile products while on probation. Respondent Pharmacy shall submit proof
satisfactory to the board of compliance with this term of probation. Failure to abide by this
restriction or to timely submit proof to the board of compliance therewith shall be considered a
violation of probation.

DISCIPLINARY ORDER AS TO RESPONDENT PHARMACIST

IT IS HEREBY ORDERED that Registered Pharmacist License No. RPH 62617 issued to
Respondent Pharmacist is revoked. However, the revocation is stayed and Respondent
Pharmacist is placed on probation for five (5) years on the following terms and conditions.

15. Obey All Laws

Respondent Pharmacist shall obey all state and federal laws and regulations.

Respondent Pharmacist shall report any of the following occurrences to the board, in
writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the
  Pharmacy Law, state and federal food and drug laws, or state and federal controlled
  substances laws
• a plea of guilty or nolo contendre in any state or federal criminal proceeding to any
criminal complaint, information or indictment
• a conviction of any crime
• discipline, citation, or other administrative action filed by any state or federal agency
which involves respondent's Registered Pharmacist License No. RPH 62617 or which
is related to the practice of pharmacy, or the manufacturing, obtaining, handling,
distributing, billing, or charging for any drug, device or controlled substance.
Failure to timely report such occurrence shall be considered a violation of probation.

16. Report to the Board
Respondent Pharmacist shall report to the board quarterly, on a schedule as directed by the
board or its designee. The report shall be made either in person or in writing, as directed. Among
other requirements, Respondent Pharmacist shall state in each report under penalty of perjury
whether there has been compliance with all the terms and conditions of probation. Failure to
submit timely reports in a form as directed shall be considered a violation of probation. Any
period(s) of delinquency in submission of reports as directed may be added to the total period of
probation. Moreover, if the final probation report is not made as directed, probation shall be
automatically extended until such time as the final report is made and accepted by the board.

17. Interview with the Board
Upon receipt of reasonable prior notice, Respondent Pharmacist shall appear in person for
interviews with the board or its designee, at such intervals and locations as are determined by the
board or its designee. Failure to appear for any scheduled interview without prior notification to
board staff, or failure to appear for two (2) or more scheduled interviews with the board or its
designee during the period of probation, shall be considered a violation of probation.

18. Cooperate with Board Staff
Respondent Pharmacist shall cooperate with the board's inspection program and with the
board's monitoring and investigation of respondent's compliance with the terms and conditions of
their probation. Failure to cooperate shall be considered a violation of probation.

///
19. **Continuing Education**

Respondent Pharmacist shall provide evidence of efforts to maintain skill and knowledge as a pharmacist as directed by the board or its designee.

20. **Notice to Employers**

During the period of probation, Respondent Pharmacist shall notify all present and prospective employers of the decision in case number 4842 and the terms, conditions and restrictions imposed on respondent by the decision, as follows:

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of Respondent Pharmacist’s undertaking any new employment, Respondent Pharmacist shall cause his direct supervisor, pharmacist-in-charge (including each new pharmacist-in-charge employed during respondent’s tenure of employment) and owner to report to the board in writing acknowledging that the listed individual(s) has/have read the decision in case number 4842, and terms and conditions imposed thereby. It shall be Respondent Pharmacist’s responsibility to ensure that his employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

If Respondent Pharmacist works for or is employed by or through a pharmacy employment service, Respondent Pharmacist must notify his direct supervisor, pharmacist-in-charge, and owner at every entity licensed by the board of the terms and conditions of the decision in case number 4842 in advance of the Respondent Pharmacist commencing work at each licensed entity. A record of this notification must be provided to the board upon request.

Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen (15) days of Respondent Pharmacist undertaking any new employment by or through a pharmacy employment service, Respondent Pharmacist shall cause his direct supervisor with the pharmacy employment service to report to the board in writing acknowledging that he or she has read the decision in case number 4842 and the terms and conditions imposed thereby. It shall be Respondent Pharmacist’s responsibility to ensure that his employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

Failure to timely notify present or prospective employer(s) or to cause that/those employer(s) to submit timely acknowledgments to the board shall be considered a violation of
probation.

"Employment" within the meaning of this provision shall include any full-time, part-time, temporary, relief or pharmacy management service as a pharmacist or any position for which a pharmacist license is a requirement or criterion for employment, whether the respondent is an employee, independent contractor or volunteer.

21. No Supervision of Interns, Serving as Pharmacist-in-Charge (PIC), Serving as Designated Representative-in-Charge, or Serving as a Consultant

During the period of probation, Respondent Pharmacist shall not supervise any intern pharmacist, be the pharmacist-in-charge or designated representative-in-charge of any entity licensed by the board nor serve as a consultant unless otherwise specified in this order.

Assumption of any such unauthorized supervision responsibilities shall be considered a violation of probation.

22. Reimbursement of Board Costs

As a condition precedent to successful completion of probation, Respondent Pharmacist shall be jointly and severally liable with Respondent Pharmacy for payment of the Board's costs of investigation and prosecution in the amount of $10,739.00. Respondent shall make said payments following a payment plan approved by the Board or its designee.

There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by Respondent Pharmacist shall not relieve Respondent Pharmacist of their responsibility to reimburse the board its costs of investigation and prosecution.

23. Probation Monitoring Costs

Respondent Pharmacist shall pay any costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.
24. **Status of License**

Respondent Pharmacist shall, at all times while on probation, maintain an active, current license with the board, including any period during which suspension or probation is tolled. Failure to maintain an active, current license shall be considered a violation of probation.

If Respondent Pharmacist’s license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof due to tolling or otherwise, upon renewal or reapplication respondent's license shall be subject to all terms and conditions of this probation not previously satisfied.

25. **License Surrender While on Probation/Suspension**

Following the effective date of this decision, should Respondent Pharmacist cease practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, Respondent Pharmacist may tender their license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, Respondent Pharmacist will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the Respondent Pharmacist’s license history with the board.

Upon acceptance of the surrender, Respondent Pharmacist shall relinquish their pocket and wall license to the board within ten (10) days of notification by the board that the surrender is accepted. Respondent Pharmacist may not reapply for any license from the board for three (3) years from the effective date of the surrender. Respondent Pharmacist shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board, including any outstanding costs.

26. **Notification of a Change in Name, Residence Address, Mailing Address or Employment**

Respondent Pharmacist shall notify the board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving, the address of the new employer, the name of the supervisor and owner, and the work schedule if known. Respondent
Pharmacist shall further notify the board in writing within ten (10) days of a change in name, residence address, mailing address, or phone number.

Failure to timely notify the board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.

27. Tolling of Probation

Except during periods of suspension, Respondent Pharmacist shall, at all times while on probation, be employed as a pharmacist in California for a minimum of 40 hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, Respondent Pharmacist must nonetheless comply with all terms and conditions of probation.

Should Respondent Pharmacist, regardless of residency, for any reason (including vacation) cease practicing as a pharmacist for a minimum of 40 hours per calendar month in California, respondent must notify the board in writing within ten (10) days of the cessation of practice, and must further notify the board in writing within ten (10) days of the resumption of practice. Any failure to provide such notification(s) shall be considered a violation of probation.

It is a violation of probation for Respondent Pharmacist’s probation to remain tolled pursuant to the provisions of this condition for a total period, counting consecutive and non-consecutive months, exceeding thirty-six (36) months.

"Cessation of practice" means any calendar month during which respondent is not practicing as a pharmacist, as defined by Business and Professions Code section 4000 et seq., for at least forty (40) hours. "Resumption of practice" means any calendar month during which respondent is practicing as a pharmacist, as defined by Business and Professions Code section 4000 et seq., for at least forty (40) hours.

28. Violation of Probation

If Respondent Pharmacist has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended, until all terms and conditions have been satisfied or the board has taken other action as
deemed appropriate to treat the failure to comply as a violation of probation, to terminate
probation, and to impose the penalty that was stayed.

If Respondent Pharmacist violates probation in any respect, the board, after giving
Respondent Pharmacist notice and an opportunity to be heard, may revoke probation and carry
out the disciplinary order that was stayed. Notice and opportunity to be heard are not required for
those provisions stating that a violation thereof may lead to automatic termination of the stay
and/or revocation of the license. If a petition to revoke probation or an accusation is filed against
Respondent Pharmacist during probation, the board shall have continuing jurisdiction and the
period of probation shall be automatically extended until the petition to revoke probation or
accusation is heard and decided.

29. Completion of Probation
Upon written notice by the board or its designee indicating successful completion of
probation, Respondent Pharmacist's license will be fully restored.

30. Restricted Practice
Respondent Pharmacist shall not prepare, oversee or participate in the preparation of
injectable sterile products while on probation. Respondent Pharmacist shall submit proof
satisfactory to the board of compliance with this term of probation. Failure to abide by this
restriction or to timely submit proof to the board of compliance therewith shall be considered a
violation of probation.

31. Remedial Education
Within sixty (60) days of the effective date of this decision, Respondent Pharmacist shall
submit to the board or its designee, for prior approval, an appropriate program of remedial
education related to compounding. The program of remedial education shall consist of at least
fifteen (15) hours per year, for five (5) years, at Respondent Pharmacist's own expense. All
remedial education shall be in addition to, and shall not be credited toward, continuing education
(CE) courses used for license renewal purposes.

Failure to timely submit or complete the approved remedial education shall be considered a
violation of probation. The period of probation will be automatically extended until such
remedial education is successfully completed and written proof, in a form acceptable to the board, is provided to the board or its designee.

Following the completion of each course, the board or its designee may require the respondent, at their own expense, to take an approved examination to test the respondent's knowledge of the course. If Respondent Pharmacist does not achieve a passing score on the examination, this failure shall be considered a violation of probation. Any such examination failure shall require respondent to take another course approved by the board in the same subject area.

32. **No New Ownership of Licensed Premises**

Respondent Pharmacist shall not acquire any new ownership, legal or beneficial interest nor serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any additional business, firm, partnership, or corporation licensed by the board. If Respondent Pharmacist currently owns or has any legal or beneficial interest in, or serves as a manager, administrator, member, officer, director, trustee, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board, Respondent Pharmacist may continue to serve in such capacity or hold that interest, but only to the extent of that position or interest as of the effective date of this decision. Violation of this restriction shall be considered a violation of probation.

33. **Consultant for Owner or Pharmacist-In-Charge**

During the period of probation, Respondent Pharmacist shall not supervise any intern pharmacist or serve as a consultant to any entity licensed by the board. Respondent Pharmacist may be a pharmacist-in-charge. However, if during the period of probation respondent serves as a pharmacist-in-charge, Respondent Pharmacist shall retain an independent consultant at his own expense who shall be responsible for reviewing pharmacy operations on a monthly basis for compliance by the pharmacy with state and federal laws and regulations governing the practice of pharmacy and for compliance by respondent with the obligations of a pharmacist-in-charge. The consultant shall be a pharmacist licensed by and not on probation with the board and whose name shall be submitted to the board or its designee, for prior approval, within thirty (30) days of the
effective date of this decision. Respondent Pharmacist shall not be a pharmacist-in-charge at
more than one pharmacy or at any pharmacy of which he is not the sole owner. Failure to timely
retain, seek approval of, or ensure timely reporting by the consultant shall be considered a
violation of probation. The board or its designee may consider a modification of this requirement
to require review of pharmacy operations on a quarterly basis.

ACCEPTANCE

I am authorized to sign for Respondent Pharmacy. I have carefully read the Stipulated
Settlement and Disciplinary Order and have fully discussed it with my attorney, Herbert L.
Weinberg. I understand the stipulation and the effect it will have on my Retail Pharmacy
Licenses. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly,
and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

DATED: 8/13/13

VISHAL B. KURDIT, Owner of SANTA CLARA
DRUG, "THE COMPOUNDING SHOP"
Respondent Pharmacy

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully
discussed it with my attorney, Herbert L. Weinberg. I understand the stipulation and the effect it
will have on my Registered Pharmacist License. I enter into this Stipulated Settlement and
Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the
Decision and Order of the Board of Pharmacy.

DATED: 8/13/13

VISHAL B. KURDIT
Respondent-Pharmacist

STIPULATED SETTLEMENT (Case No. 4842)
I have read and fully discussed with Respondent Vishal B. Puri the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.

DATED: 8/14/13

HERBERT L. WEINBERG
Attorney for Respondent

ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Board of Pharmacy of the Department of Consumer Affairs.

Dated: 7/14/13

Respectfully submitted,

KAMALA D. HARRIS
Attorney General of California

JOSHUA A. ROOM
Supervising Deputy Attorney General

ROSALIDA PEREZ
Deputy Attorney General
Attorneys for Complainant

SF3013425145
20716962.doc
Exhibit A

Accusation No. 4842
Complainant alleges:

PARTIES

1. Virginia Herold (Complainant) brings this Accusation solely in her official capacity as the Executive Officer of the Board of Pharmacy (Board), Department of Consumer Affairs.

2. On or about March 8, 2013, the Board of Pharmacy issued Retail Pharmacy License Number PHY 51229 to ERA Pharmacy Inc., dba Santa Clara Drug "The Compounding Shop" (Respondent Pharmacy). The Retail Pharmacy License was in full force and effect at all times relevant to the charges brought herein and will expire on September 4, 2013, unless renewed.

3. On or about July 28, 2009, the Board of Pharmacy issued Registered Pharmacist
License Number RPH 62617 to Vishal B. Purohit (Respondent Pharmacist). The Registered Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on November 30, 2014, unless renewed.

**JURISDICTION**

4. This Accusation is brought before the Board under the authority of the following laws. All section references are to the Business and Professions Code (Code) unless otherwise indicated.

5. Code section 4011 provides that the Board shall administer and enforce both the Pharmacy Law [Bus. & Prof. Code § 4000 et seq.] and the Uniform Controlled Substances Act [Health & Safety Code, § 11000 et seq.].

6. Code section 4300 provides that every license issued by the Board may be suspended or revoked.

7. Code section 4300.1 provides that the expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.

**STATUTORY AND REGULATORY PROVISIONS**

8. Code section 4081 provides, in pertinent part that:

"(a) All records of manufacture and of sale, acquisition, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. A current inventory shall be kept by every manufacturer, wholesaler, pharmacy, veterinary food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or establishment holding a currently valid and unrevoked certificate, license, permit, registration, or exemption under Division 2 (commencing with Section 1200) of the Health and Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and
Institutions Code who maintains a stock of dangerous drugs or dangerous devices.

"(b) The owner, officer, and partner of any pharmacy, wholesaler, or veterinary food-animal drug retailer shall be jointly responsible, with the pharmacist-in-charge or representative-in-charge, for maintaining the records and inventory described in this section.

9. Code section 4113, subdivision (c), provides that the pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.

10. Code section 4127.1 provides, in pertinent part, that unless exempted due to accreditation by a private accreditation agency approved by the Board, a pharmacy shall not compound injectable sterile drug products in this state unless the pharmacy has obtained a license from the Board pursuant to this section, that the license shall be renewed annually and is not transferable, and that a license to compound injectable sterile drug products may not be issued or renewed until the location has been inspected by the Board and found in compliance.

11. Code section 4301 provides, in pertinent part that:

"The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

"...

"(g) The violation of any of the statutes of this state, or any other state, or of the United States regulating controlled substances and dangerous drugs.

"...

"(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency.

"...

12. Code section 4332 makes it unlawful for any person to fail, neglect, or refuse to...
maintain the records required by section 4081 or, when called upon by an authorized officer or a
member of the board, to refuse to produce or provide the records within a reasonable time, or to
willfully produce or furnish records that are false.

13. Code section 4342, subdivision (a), states that the Board may institute any action or
actions as may be provided by the law and that, in its discretion, are necessary, to prevent the sale
of pharmaceutical preparations and drugs that do not conform to the standard and tests as to
quality and strength, provided in the latest edition of the United States Pharmacopoeia or National
Formulary, or that violate any provision of the Sherman Food, Drug, and Cosmetic Law.

14. California Code of Regulations, title 16, section 1714 provides, in pertinent part, that
each pharmacy licensed by the board shall maintain its facilities, space, fixtures, and equipment
so that drugs are safely and properly prepared, maintained, secured and distributed.

15. California Code of Regulations, title 16, section 1715 requires, in pertinent part, that
the pharmacist-in-charge of each pharmacy complete, using a form specified by the regulation
and available from the Board, a self-assessment of the pharmacy’s compliance with federal and
state pharmacy law before July 1 of each odd-numbered year and within thirty (30) days
whenever a new pharmacy permit has been issued, there is a change in the pharmacist-in-charge,
or there is a change in the licensed location of the pharmacy. Each pharmacy self-assessment
form shall be kept on file in the pharmacy for three (3) years from the date of completion.

16. California Code of Regulations, title 16, section 1735.2, subdivision (j), states, in
pertinent part, that prior to allowing any drug product to be compounded in a pharmacy, the
pharmacist-in-charge shall complete a self-assessment for compounding pharmacies using a form
specified by the regulation and available from the Board, and that the self-assessment form shall
be thereafter completed before July 1 of each odd-numbered year, and within thirty (30) days of
the start of a new pharmacist-in-charge or issuance of a new pharmacy license.

17. California Code of Regulations, title 16, section 1735.3 lists records that are required
to be created and maintained in a readily retrievable form by the pharmacy for three (3) years, for
each compounded drug product prepared by a pharmacy; subdivisions (a)(5) and (a)(6) thereof
require that for each compounded drug product pharmacy records include the quantity of each
component used in compounding the drug product ((a)(5)) and the manufacturer and lot number 
of each component, unless the manufacturer name is demonstrably unavailable in which case the 
name of the supplier may be substituted ((a)(6)).

18. California Code of Regulations, title 16, section 1751.1 lists additional records that 
are required to be created and maintained in a readily retrievable form by the pharmacy for three 
(3) years, for each sterile injectable compounded drug product prepared by a pharmacy; 
subdivision (b)(6) thereof requires that for sterile products compounded from one or more non-
sterile ingredients, a pharmacy keep records of preparation including the master worksheet, the 
preparation work sheet, and records of end-product evaluation results.

19. California Code of Regulations, title 16, section 1751.7 requires, in pertinent part, 
that a pharmacy engaged in compounding sterile injectable drug products maintain, as part of its 
written policies and procedures, a written quality assurance plan including, inter alia, a periodic 
sampling plan for examination of end product, and further requires that batch-produced sterile 
injectable drug products compounded from one or more non-sterile ingredients shall be subject to 
documented end product testing for sterility and pyrogens and shall be quarantined until the end 
product testing confirms sterility and acceptable levels of pyrogens.

COST RECOVERY

20. Code section 125.3 states, in pertinent part, that the Board may request the 
administrative law judge to direct a licentiate found to have committed a violation or violations of 
the licensing act to pay a sum not to exceed the reasonable costs of the investigation and 
enforcement of the case.

CONTROLLED SUBSTANCES/DANGEROUS DRUGS

21. Code section 4022 states, in pertinent part, that:

"Dangerous drug" or "dangerous device" means any drug or device unsafe for self-use in 
humans or animals, and includes the following:

"(a) Any drug that bears the legend: "Caution: federal law prohibits dispensing without 
prescription," "Rx only," or words of similar import.

"(b) Any device that bears the statement: "Caution: federal law restricts this device to sale
by or on the order of a ________, "Rx only," or words of similar import, the blank to be filled in with the designation of the practitioner licensed to use or order use of the device.

"(c) Any other drug or device that by federal or state law can be lawfully dispensed only on prescription or furnished pursuant to Section 4006."

22. Alprostadil is a dangerous drug as designated by Code section 4022.

FACTUAL BACKGROUND

23. On or about June 18, 2013, two Board Inspectors inspected Respondent Pharmacy after receiving a complaint against Respondent Pharmacy alleging a contaminated sterile environment, use of expired ingredients in compounding drug products, and failure to perform qualitative and quantitative testing on sterile compounded products. They were met and assisted by Respondent Pharmacist. During the course of that inspection, the Inspector(s) discovered:

a. That Respondents had been engaged in sterile injectable drug compounding in and/or between March and June 2013, despite the pharmacy's lack of licensure to do so;

b. That Respondents had compounded multiple batch-produced sterile injectable drug products from one or more non-sterile ingredients between April and June 2013, and released those products for sale and/or patient administration, without first quarantining those drug products until receipt of results of end product testing for sterility and pyrogens;

c. That Respondents had compounded multiple batch-produced sterile injectable drug products from one or more non-sterile ingredients between April and June 2013 for which there were no records of end product testing for sterility and pyrogens;

d. That Respondents had inadequate compounding records, including that there were no compounding records available for alprostadil aliquots lot number 90000ALIQ used in sterile injectable compounded products between April and June 2013;

e. That Respondents had not completed a new pharmacy self-assessment form or a compounding self-assessment form since the new pharmacy permit was issued or there was a change in the pharmacist-in-charge; and

f. That Respondents kept multiple expired medications throughout the pharmacy's extemporaneous compounding area, sterile injectable product compounding area,
FIRST CAUSE FOR DISCIPLINE
(Unlicensed Activity)

24. Respondents are subject to discipline pursuant to Code sections 4301, subdivisions (j) and (o), and/or 4113, subdivision (c), and/or 4127.1, in that, as described in paragraph 24 above, Respondents compounded sterile injectable drug products from about March 2013 through June 2013 without having obtained a sterile compounding license from the Board.

SECOND CAUSE FOR DISCIPLINE
(Failure to Comply with Sterile Injectable Compounding Quality Assurance and Process)

25. Respondents are subject to discipline pursuant to Code sections 4301, subdivisions (j) and (o), and/or 4113, subdivision (c), and/or California Code of Regulations, title 16, section 1751.7, in that, as described in paragraph 24 above, Respondents compounded multiple batch-produced sterile injectable drug products from one or more non-sterile ingredients and released them for sale to physicians for office use without first quarantining the sterile injectable drugs for end product testing for sterility and pyrogens.

THIRD CAUSE FOR DISCIPLINE
(Failure to Comply with Sterile Injectable Recordkeeping Requirements)

26. Respondents are subject to discipline pursuant to Code sections 4301, subdivisions (j) and (o), and/or 4113, subdivision (c), and/or California Code of Regulations, title 16, sections 1735.3, and/or 1751.1, in that, as described in paragraph 24 above, Respondents failed to make and keep records that included the master work sheet, the preparation work sheet, and records of end-product evaluation results for multiple batch-produced sterile injectable drug products that were compounded from one or more non-sterile ingredients, including the alprostadil aliquots, lot number 90000ALIQ, used in sterile injectable compounded products between April 2013 and June 2013.
FOURTH CAUSE FOR DISCIPLINE

(Failure to Complete Pharmacy Self-Assessment)

27. Respondents are subject to discipline pursuant Code sections 4301, subdivisions (j) and (o), and/or 4113, subdivision (c), and/or California Code of Regulations section 1715, in that, as described in paragraph 24 above, the Respondent Pharmacist did not complete a self-assessment within 30 days of the new pharmacy permit being issued or when Respondent Pharmacist became the new Pharmacist-in-Charge.

FIFTH CAUSE FOR DISCIPLINE

(Failure to Complete Compounding Self-Assessment)

28. Respondents are subject to discipline pursuant Code sections 4301, subdivisions (j) and (o), and/or 4113, subdivision (c), and/or California Code of Regulations section 1735.2, in that Respondent Pharmacist did not complete a self-assessment form for compounding pharmacies prior to compounding drugs in the pharmacy.

SIXTH CAUSE FOR DISCIPLINE

(Drugs Lacking Quality/Strength)

29. Respondents are subject to discipline pursuant to Code sections 4301, subdivisions (j) and (o), and/or 4113, subdivision (c), and/or 4342, subdivision (a), and/or California Code of Regulations, title 16, section 1714, in that, as described in paragraph 24 above, there were multiple expired drugs throughout the pharmacy in violation of operational standards.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

1. Revoking or suspending Retail Pharmacy License Number PHY 51229, issued to ERA Pharmacy Inc., dba Santa Clara Drug "The Compounding Shop" (Respondent Pharmacy);

2. Revoking or suspending Registered Pharmacist License Number RPH 62617, issued to Vishal B. Purohit (Respondent Pharmacist);

3. Ordering Respondents to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section
4. Taking such other and further action as is deemed necessary and proper.

DATED: 7/24/13

ROSALIDA BRY

VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

SF2013405145
20712674.doc